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ABSTRACT 
 
 
CAROLYN L. LEKAVICH: The Identification of Biomarkers that Predict Impending Heart 
Failure Preserved Ejection Fraction (HFpEF) 
(Under the direction of Dr. Debra J. Barksdale) 
 
 
The overall purpose of this investigation was to utilize pathophysiologic, 
methodologic and empirical approaches to address gaps in our understanding about the 
identification of biomarkers that predict impending HFpEF.  To guide this exploration, three 
papers were developed that outline the current scope of the problem, define strategies to 
contribute to the current science, analyze the patient population, report the results of one 
empirical study and report on the impact and implications for future research. 
 
 
 
 
 
 
 
 
 
 
  
iv 
 
ACKNOWLEDGEMENTS 
 
 
The privilege of pursuing my PhD over the last four and a half years has brought 
many incredible gifts into my life.  I have deep appreciation for many family members, 
friends, and colleagues and for the experiences that this journey enabled.   
Throughout this process I consistently relied on my spiritual practice and the primary 
themes of kindness and respect.   
To my mother, Florence, for her unwavering support and love regardless of the 
situation or time.  I know that Dad would have loved to have shared this time with us.  To my 
daughter Venia who teaches me every day about what matters most in life.  To my brothers 
Ken, Tom, late brother, Barry, and my sister in law, Mary, thank you for your care and 
willingness to ‘always be there’.  To my godmother, MaryAnn, who is a mentor and inspired 
me to become a nurse. 
For my friends who supported me through the entire process, I’d like to thank Sandee, 
Ellen, Judie and Christine who helped me stay focused and grounded.  To my colleagues at 
work, especially Midge Bowers, Allison Dimsdale and Karol Harshaw-Ellis, thank you for 
your ongoing support, inspiration and example of professionalism and caring.  
So many components of the research process had to come together to support the 
completion of this dissertation.  I would especially like to acknowledge Mike Foster, RCW, 
RDCS, Michel Khouri, MD, Seanna Horan, Virginia Carden, and Jean Woolard, RCS, 
v 
RDCS.  And to Dr. Eric Velazquez, who has consistently been a mentor and advocate of my 
clinical and research aspirations over the last 16 years.  
To my dissertation committee, I will always be appreciative of your guidance and 
expertise.  A sincere thank you to Drs. Debra Barksdale, Eric Velazquez, Jamie Crandell, 
Virginia Neelon and Jia-Rong Wu, I am appreciative of your wisdom, insights, and high 
ethical and academic standards.  A special note of gratitude to Dr. Barksdale, as my 
dissertation chair; I am sincerely grateful for your consistent support, insight and mentorship.   
  
vi 
 
TABLE OF CONTENTS 
 
 
LIST OF TABLES ................................................................................................................... ix 
 
Chapter 
 
 I. INTRODUCTION ................................................................................................1 
 
Statement of the Problem ......................................................................................2 
 
Purpose ..................................................................................................................2 
 
Background and Significance ...............................................................................3 
 
Research Proposal .................................................................................................9 
 
Manuscript Organization ....................................................................................10 
 
 II. PAPER 1:  “HEART FAILURE PRESERVED EJECTION FRACTION 
(HFpEF) STATE OF THE SCIENCE:  AN INTEGRATED AND STRATEGIC 
REVIEW” ....................................................................................................................12 
 
Overview .............................................................................................................12 
 
Background .........................................................................................................14 
 
Physiology...........................................................................................................16 
 
Biomarkers ..........................................................................................................18 
 
Guidelines ...........................................................................................................23 
 
Treatment ............................................................................................................25 
 
Population ...........................................................................................................29 
 
Conclusion ..........................................................................................................30 
 
vii 
 III. PAPER 2: “COMPARING NOVEL BIOMARKERS ASSOCIATED WITH 
HEART FAILURE PRESERVED EJECTION FRACTION (HFpEF):  A 
MATCHED CASE-CONTROL ANALYSIS” ............................................................32 
 
Overview .............................................................................................................32 
 
Background .........................................................................................................34 
 
Methods...............................................................................................................36 
 
Sample and Setting .............................................................................................37 
 
Results .................................................................................................................41 
 
Discussion ...........................................................................................................44 
 
Limitations ..........................................................................................................45 
 
Conclusion ..........................................................................................................46 
 
 IV. PAPER 3: “INCIDENT HEART FAILURE PRESERVED EJECTION 
FRACTION (HFpEF):  RECOGNIZING KEY PATIENT ATTRIBUTES” ..............47 
 
Overview .............................................................................................................47 
 
Background .........................................................................................................49 
 
Methods...............................................................................................................52 
 
Results .................................................................................................................55 
 
Discussion ...........................................................................................................58 
 
Limitations ..........................................................................................................60 
 
Conclusion ..........................................................................................................61 
 
 V. DISCUSSIONS AND CONCLUSIONS ............................................................62 
 
Summary .............................................................................................................62 
 
Implications for Nursing Research .....................................................................64 
 
Implications for Nursing Practice .......................................................................65 
 
Conclusion ..........................................................................................................66 
viii 
 
APPENDICES .........................................................................................................................68 
 
REFERENCES ........................................................................................................................75 
  
ix 
LIST OF TABLES 
 
 
Tables 
 
 3.1 Comparison of Biomarkers for the Matched Case-Control ................................43 
 
 3.2 Conditional Logistic Regression Results ............................................................44 
 
 4.1 Characteristics of Incident HFpEF ......................................................................56 
 
 4.2 Age of Incident HFpEF at Diagnosis by Race ....................................................56 
 
 4.3 Physiologic Markers of Incident HFpEF ............................................................57 
 
 4.4 Echo biomarkers of Incident HFpEF ..................................................................57 
 
 
1 
 
 
CHAPTER 1 
 
INTRODUCTION 
 
 
Heart failure (HF) is a clinical syndrome defined by characteristic symptoms and 
physical findings resulting from structural or functional impairment of left ventricular (LV) 
filling or ejection in which the heart is unable to pump enough blood to meet the metabolic 
needs of the body (Borlaug & Paulus, 2011; Redfield et al., 2003; Yancy et al., 2013).  Based 
on HF guidelines published in 2013 by the American College of Cardiology Foundation 
(ACCF)/American Heart Association (AHA), HF can result from disorders of the great 
vessels, myocardium, endocardium, pericardium, heart valves and from metabolic 
abnormalities, however, most commonly HF is a disease of the left ventricle (LV) (Yancy et 
al., 2013). 
The pathophysiological understanding of HF has changed notably over the last 25 
years (Little & Zile, 2012).  Previously, HF was typically associated with ischemia due to 
coronary artery disease that resulted in LV systolic dysfunction “pump failure” with reduced 
ejection fraction (EF).  With emerging evidence that symptoms of HF could be associated 
with a wide range of LV function ranging from severe dilatation and reduced EF to preserved 
EF suggested that HF was not just a condition of systolic dysfunction (Little & Zile, 2012; 
Yancy et al., 2013).  Terminology evolved to include HF syndromes with EF >50% 
described as diastolic heart failure (DHF) and as the pathophysiological mechanisms of HF 
became clearer the terms were changed to heart failure preserved ejection fraction (HFpEF) 
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and heart failure reduced ejection fraction (HFrEF) (Little & Zile, 2012).  The extent to 
which HFpEF and HFrEF overlap versus represent distinct phenotypes is controversial 
(Owan et al., 2006).  A more recent paradigm suggests that HFPEF is a pro-inflammatory 
state driven by multiple co-morbidities (Paulus & Tschope, 2013). 
To more precisely describe this syndrome, the term HF is not synonymous with terms 
such as cardiomyopathy or LV systolic or diastolic dysfunction; instead these terms describe 
possible structural or physiological states that contribute to HF (Yancy et al., 2013).  To be 
comprehensive in describing the scope of this syndrome a list of conditions that may 
contribute to the development of HF include: a) familial causes (found through genotyping), 
b) metabolic causes; obesity (excessive adipose tissue causing an increase in circulating 
blood volume), diabetic (considered a risk factor for HF), thyroid disease (hyperthyroidism 
associated with sinus tachycardia or hypothyroidism associated with bradycardia and 
decreased ventricular filling), c) toxic causes; alcohol (causes biventricular dysfunction and 
dilation), cocaine (dilatation), cancer therapies/chemotherapy (anthracyclines, Herceptin, 
cyclophosphadmide, taxoids, mitomycin-C, 5-fluirouracil and interferons, d) other toxins 
causes; ephedra, anabolic steroids, chloroquine, clozapine, amphetamine, methyphenidate 
and catecholamines and nutritional deficiencies such as anorexia, AIDS, pregnancy (thiamine 
deficiency related) definciency in l-carnitiine, e) tachycardia induced causes; (duration and 
rate of the increased heart rate) such as atrial fibrillation with rapid ventricular rate or 
supraventricular tachycardia, f) inflammatory/infectious causes; postvirus, medications, 
systemic diseases such as systemic lupus erythematosus, HIV cardiomyopathy, post partum 
cardiomyopathy, giant cell, refractory ventricular arrthymias, Chagas (biventricular 
enlargement, thinning or thickening of ventricular walls, apical aneurysms and mural 
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thrombi), g) inflammatory/noninfectious causes; allergy/hypersensitivity (peripheral 
eosinophilia-drug induced such as Amphtericin B, streptomycin, phentyoin, isoniazid, 
tetanus toxoid, hydrocholorthiazaide, dobutamine, chlorthalidone), rheumatologic/connective 
tissue (pericarditis, pericardial effusion atrioventricular heart block), scleroderma, peripartum 
cardiomyopathy (last trimester of pregnancy, risk factors maternal age, mulitparity, African 
descent- focus on hemodynamic and immunologic causes), iron overload (hemochromatosis, 
beta thalassemia major), amyloidosis (deposition of insoluble proteins as fibrils in the heart, 
3-4% of African Americans carry an amyloidogenic allele of the human serum protein 
transthyretic which appears to increase cardiac amyloid deposition), sarcoidosis (cardiac 
sarcoid may affect as many as 25% of patients with sarcoid), stress (Takotsubo) (acute 
reversible LV dysfunction in the absence of significant CAD, triggered by acute emotional or 
physical stress with a distinctive pattern of apical ballooning that most often affects 
postmenopausal women with similar presentation to acute coronary syndrome) (Yancy et al., 
2013). 
Physiology of Diastolic and Systolic Function 
Diastole starts when the aortic valve closes and includes LV pressure fall, rapid 
filling, diastasis and atrial contraction (Brutsaert, Sys, & Gillebert, 1993).  Key aspects of 
diastolic function are:  a) myocardial relaxation and passive LV filling, properties modulated 
by myocardial tone, b) myocardial relaxation determined by load, and c) myocardial stiffness 
determined by the myocardial cell and interstitial matrix (Wang & Nagueh, 2009).   
Systole starts when the mitral valve closes and lasts until aortic valve closes (Otto, 
2004).  In terms of ventricular pressure changes, systole begins when LV diastolic pressure 
exceeds left atrial pressure, resulting in closure of the mitral valve, ventricular pressure 
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increases, exceeds aortic pressure and the aortic valve opens, ejection occurs, LV volume 
drops and the aortic valve closes (Otto, 2004).  LV systolic function is best described by 
contraction and is affected by heart rate, preload and afterload (Otto, 2004).   
Optimal performance of the LV is dependent upon the ability of heart to cycle two 
states; a) a compliant left ventricle that allows the LV to fill during diastole from low left 
atrial pressures, and b) a firm LV chamber in systole that ejects the stroke volume (volume of 
blood pumped from one ventricle of the heart with each beat) at arterial pressures (Wang & 
Nagueh, 2009).  In addition, the stroke volume (SV) must accommodate to meet the 
metabolic needs of the body, as with exercise without much increase in left atrial (LA) 
pressure (Brutsaert et al., 1993).   
The primary measurements of systolic function are measures of contractility that 
include EF, cardiac output (CO) and SV (Otto, 2004).  Global cardiac function is most 
commonly assessed with echo by measuring the EF (Otto, 2004).  EF is directly calculated 
from ventricular volumes and is load dependent, rather than a true measure of cardiac 
contractility (Braunwald & Zipes, 2001).  Although EF may not consistently be a valid or 
reliable estimate of true myocardial contractility, it is the most commonly used method for 
assessing LV function (Feigenbaum, Armstrong, & Ryan, 2005).  As a result, myocardial EF 
is used as an important classification in distinguishing patient demographics, co-morbid 
conditions, prognosis and treatment (Yancy et al., 2013).  It is recognized that most HF 
patients may have varying degrees of systolic and diastolic LV abnormalities not reflected in 
the EF (Borlaug & Paulus, 2011).  Although EF is maintained in HFpEF, myocardial systolic 
function and LV systolic elastance, (Ees) is not normal (Gladden, Linke, & Redfield, 2014).  
Studies have confirmed that Ees is increased in the setting of impaired myocardial 
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contractility (systole) suggesting a reduction in myocardial contractility (Borlaug & Paulus, 
2011).  This is an important pathophysiological finding given that reduced myocardial 
contractility has been associated with increased mortality (Borlaug, Lam, Roger, Rodeheffer, 
& Redfield, 2009).  As a measure of systolic function, contractility is more accurately 
represented by measures that reflect the interaction of ventricular and arterial elastance 
(Borlaug & Paulus, 2011).   
Diastolic and Systolic Dysfunction 
The two main mechanisms involved in diastolic dysfunction (DD) are abnormal 
relaxation and passive stiffness (decreased compliance of the LV) that manifests as 
prolonged isovolumetric relaxation, slow LV filling and increased diastolic stiffness as the 
cause (Braunwald & Zipes, 2001; Libby, 2008).  Cardiac relaxation is dependent upon 
calcium (Ca2+) reuptake and elastic recoil related directly to the sarcoplasmic reticulum Ca2 
ATPase pump (Gladden et al., 2014).  Elevated filling pressures are the main physiological 
consequence of diastolic dysfunction (Brutsaert et al., 1993).  As an important early finding, 
LV pressures and relaxation can be normal at rest, exercise testing can reveal impaired LV 
relaxation at elevated heart rates (measured by elevated LV mean and LV end diastolic 
pressure LVEDP) (Hay, Rich, Ferber, Burkhoff, & Maurer, 2005) 
In previous studies evaluating potential causes of HFpEF, DD was considered a 
primary antecedent to HFpEF (Hanrath, Mathey, Siegert, & Bleifeld, 1980).  HFpEF was 
commonly thought to represent a process of maladaptive age and HTN related remodeling 
which resulted in DD (Dunlay, Roger, Weston, Jiang, & Redfield, 2012).  However, with the 
progression of Doppler echo imaging and new science describing physiology, evidence of 
DD was found to be one of several factors that impact the development of HFpEF (Borlaug 
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& Paulus, 2011).  Other factors with important mechanisms underlying HFpEF include 
resting and exercise systolic dysfunction, impaired ventricular-arterial coupling, chronotropic 
incompetence (Borlaug, Olson, et al., 2010; Dunlay et al., 2012), endothelial dysfunction, 
microvascular CAD (Borlaug & Paulus, 2011) and pulmonary arterial hypertension (Lam et 
al., 2009).   
HFpEF is typically characterized by EF>50% (Borlaug & Paulus, 2011).  Four sets of 
diagnostic criteria for the diagnosis of HFpEF have so far been published from ("How to 
diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure," 1998; 
Paulus et al., 2007; Vasan & Levy, 2000; Yturralde & Gaasch, 2005).  All of the guidelines 
require the presence of signs or symptoms of HF, evidence of normal systolic LV function, 
and evidence of diastolic dysfunction or surrogate markers that include LV hypertrophy, LA 
enlargement, atrial fibrillation or elevated BNP levels (Paulus et al., 2007).  None of the 
guidelines have been validated (Borlaug & Paulus, 2011) and consistent use in the literature 
is lacking.  The first set came from the Working Group on Myocardial Function of the 
European Society of Cardiology ("How to diagnose diastolic heart failure. European Study 
Group on Diastolic Heart Failure," 1998).  The second set came from the National Heart 
Lung Blood Institute Framingham Heart Study in which invasive evidence of diastolic 
dysfunction was required (Vasan & Levy, 2000).  The third set came from the Lahey Clinic 
where a scoring system was designed along with surrogate markers for DD by LVH and LAE 
(Yturralde & Gaasch, 2005).  The last set of guidelines came from the ESC requiring signs 
and symptoms of HF, LVEF >50%, evidence of DD (elevated left ventricular end diastolic 
pressure (LVEDP)>16mmHg, pulmonary capillary wedge pressure>12mmHg, E/E’>15, 
mitral flow velocity Doppler signal showing E/A ratio<0.5+deceleration time (DT) >280ms, 
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LA size>40mL/m2, or LV mass>149g/m2-men or >122g/m2-women (Paulus et al., 2007).  
In addition the ACCF/ACC 2013 HF Guidelines for the Management of Heart Failure 
published a chart with HFpEF and HFrEF definitions (Yancy et al., 2013); however, a 
specific endorsement of HFpEF diagnostic criteria was not mentioned.  Lastly, no 
improvements in early detection or therapeutic intervention for HFpEF have been established 
within the last two decades (Owan et al., 2006).   
As a measure of systolic function, contractility is more accurately represented by 
measures that reflect the interaction of ventricular and arterial elastance (Borlaug & Paulus, 
2011).  The impact of ventricular-arterial (vascular) coupling (measured by the ratio of 
effective arterial elastance (Ea) to LV end systolic elastance (Ees) may play a key role in 
understanding the pathogenesis of HFpEF (Borlaug & Redfield, 2011).   
Diastolic and Systolic Dysfunction 
The two main mechanisms involved in diastolic dysfunction (DD) are abnormal 
relaxation and passive stiffness (decreased compliance of the LV) that manifests as 
prolonged isovolumetric relaxation, slow LV filling and increased diastolic stiffness as the 
cause (Braunwald & Zipes, 2001; Libby, 2008).  Cardiac relaxation is dependent upon 
calcium (Ca2+) reuptake and elastic recoil related directly to the sarcoplasmic reticulum Ca2 
ATPase pump (Gladden et al., 2014).  Elevated filling pressures are the main physiological 
consequence of diastolic dysfunction (Brutsaert et al., 1993).  As an important early finding, 
LV pressures and relaxation can be normal at rest, exercise testing can reveal impaired LV 
relaxation at elevated heart rates (measured by elevated LV mean and LV end diastolic 
pressure LVEDP) (Hay et al., 2005) 
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In previous studies evaluating potential causes of HFpEF, DD was considered a 
primary antecedent to HFpEF (Hanrath et al., 1980).  HFpEF was commonly thought to 
represent a process of maladaptive age and HTN related remodeling which resulted in DD 
(Dunlay et al., 2012).  However, with the progression of Doppler echo imaging and new 
science describing physiology, evidence of DD was found to be one of several factors that 
impact the development of HFpEF (Borlaug & Paulus, 2011).  Other factors with important 
mechanisms underlying HFpEF include the inflammatory effect of multiple co-morbidities, 
resting and exercise systolic dysfunction, impaired ventricular-arterial coupling, chronotropic 
incompetence (Borlaug, Olson, et al., 2010; Dunlay et al., 2012) endothelial dysfunction, 
microvascular CAD (Borlaug & Paulus, 2011) and pulmonary arterial hypertension (Lam et 
al., 2009).   
HFpEF is typically characterized by EF>50% (Borlaug & Paulus, 2011).  Four sets of 
diagnostic criteria for the diagnosis of HFpEF have so far been published from ("How to 
diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure," 1998; 
Paulus et al., 2007; Vasan & Levy, 2000; Yturralde & Gaasch, 2005).  All of the guidelines 
require the presence of signs or symptoms of HF, evidence of normal systolic LV function, 
evidence of diastolic dysfunction or surrogate markers that include LV hypertrophy, LA 
enlargement, atrial fibrillation or elevated BNP levels (Paulus et al., 2007).  None of the 
guidelines have been validated (Borlaug & Paulus, 2011) and consistent use in the literature 
is lacking.  The first set came from the Working Group on Myocardial Function of the 
European Society of Cardiology ("How to diagnose diastolic heart failure. European Study 
Group on Diastolic Heart Failure," 1998).  The second set came from the National Heart 
Lung Blood Institute Framingham Heart Study in which invasive evidence of diastolic 
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dysfunction was required (Vasan & Levy, 2000).  The third set came from the Lahey Clinic 
where a scoring system was designed along with surrogate markers for DD by LVH and LAE 
(Yturralde & Gaasch, 2005).  The last set of guidelines came from the ESC requiring signs 
and symptoms of HF, LVEF >50%, evidence of DD (elevated left ventricular end diastolic 
pressure (LVEDP)>16mmHg, pulmonary capillary wedge pressure>12mmHg, E/E’>15, 
mitral flow velocity Doppler signal showing E/A ratio<0.5+deceleration time (DT) >280ms, 
LA size>40mL/m2, or LV mass>149g/m2-men or >122g/m2-women (Paulus et al., 2007).  
In addition the ACCF/ACC 2013 HF Guidelines for the Management of Heart Failure 
published a chart with HFpEF and HFrEF definitions (Yancy et al., 2013); however, a 
specific endorsement of HFpEF diagnostic criteria was not mentioned.  Lastly, no 
improvements in early detection or therapeutic intervention for HFpEF have been established 
within the last two decades (Owan et al., 2006).   
Substantial evidence supports the enormity of the HFpEF as a major public health 
problem requiring focused inquiry.  HFpEF is without treatment, lacks consistent diagnostic 
criteria, is without defined early markers and there is controversy in defining those most 
affected (Gladden et al., 2014; Yancy et al., 2013).  To build on the current science of HFpEF 
the following study plan outlines a research guide to address the gaps outlined in the current 
literature.  The study design was an observational retrospective secondary data analysis that 
included:  a) retrospective matched case-control analysis and b) an analysis of the case group. 
Research plan 
The dissertation was organized into three publishable manuscripts.  The first 
manuscript (Chapter 2) presents an integrated and strategic review of the current literature on 
HFpEF.  The purpose of this manuscript is to present the current state of the science on 
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HFpEF, demonstrate gaps in the literature and suggest new approaches to study the syndrome 
of HFpEF.  This paper includes a description of patient characteristics, pathophysiology, 
current role and definitions of echocardiography and physiological markers, diagnostic 
criteria, treatment approaches and outcomes.   
The second manuscript (Chapter 3) presents the original data based findings from a 
retrospective matched case-control study. This paper presents the results of this proposed 
study that analyzes the differences between the case group (patients discharged with incident 
HFpEF) and the control group (no prior history of HFpEF or HFrEF), matched by age, race 
and sex, on echocardiographic and physiologic markers.   
The third manuscript (Chapter 4) presents an analysis of the incident HFpEF patient 
population.  This paper presents key details about race, age at diagnosis and time to death as 
it relates to incident HFpEF. 
The final chapter consists of an overall discussion and conclusion.  The purpose of 
this chapter is to integrate findings from each of the three publishable manuscripts that 
synthesize the current literature, study methodology and results and implications for research 
and practice.  In summary, this dissertation report includes background and significance, a 
review of the literature, results of an empirical study, an analysis of the incident HFpEF 
patient population and a synthesis and discussion of the three papers.   
Study aims 
The overall purpose of this dissertation is to identify biomarkers that predict 
impending HFpEF but precedes the actual onset of HFpEF.  This study addressed the 
following hypotheses: 1) that subjects with HFpEF demonstrate differences in biomarkers 
compared to subjects without HFpEF/HF, 2) within the subgroups of HFpEF patients, 
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age/race/sex function as moderators that impact the extent to which biomarkers predict 
HFpEF, and 3) case group analysis of the incident HFpEF group demonstrate differences in 
key attributes that define this patient population.  The impact of this study contributes to the 
current literature by enabling early recognition of potential biomarkers that precede the 
development of HFpEF, use of diagnostic criteria to consistently identify the patient 
population and provides new perspectives on the populations most affected, thus making a 
substantial contribution to the current science of HFpEF. 
.
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CHAPTER 2 
 
 
PAPER 1: HEART FAILURE PRESERVED EJECTION FRACTION (HFpEF):  AN 
INTEGRATED AND STRATEGIC REVIEW 
 
 
Overview 
Background 
In the United States (U.S.), 5.1 million Americans >20 years have heart failure (HF) and 
heart failure preserved ejection fraction (HFpEF) accounts for at least 50% of all hospital 
admissions for HF.  HFpEF has no single guideline for diagnosis or treatment, the patient 
population that is heterogeneously and inconsistently described and longitudinal studies are 
lacking.   
Objective 
The primary aims of this manuscript were to present an integrated review of the current state 
of the science on heart failure preserved ejection fraction (HFpEF), demonstrate gaps in the 
literature and provide the rationale for the design and implementation of future research to 
yield insight into the syndrome of HFpEF. 
Methods 
The scientific literature was comprehensively reviewed on HFpEF pathophysiology, patient 
characteristics, diagnostic criteria, echocardiography biomarkers, treatment approaches and 
outcomes.  Discrepancies in patient characteristics, diagnostic criteria, study methods, and 
echocardiographic biomarkers were identified. 
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Discussion 
This review indicates that no single test or guideline exists for diagnosis or treatment for 
HFpEF; heterogeneity of the population is complicated by multiple comorbidities that factor 
into onset, race and age are likely important factors and the absence of longitudinal studies 
that identify early markers of impending HFpEF.  Studies designed and powered to include 
race and age stratification, concisely defined biomarkers and consistent use of defined 
diagnostic criteria are critical study attributes for future HFpEF research.   
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PAPER 1:  HEART FAILURE PRESERVED EJECTION FRACTION (HFpEF):  AN 
INTEGRATED AND STRATEGIC REVIEW 
 
 
Objective 
This manuscript presents an integrated review of the current state of the science on 
heart failure preserved ejection fraction (HFpEF), demonstrates gaps in the literature and 
provides the rationale for the design of future research.  A description of current theories of 
pathophysiology and associated biomarkers, limitations of the current diagnosis and 
treatment guidelines and inconsistencies in defining the patient populations most affected by 
incident HFpEF are key areas of focus. 
Background 
Heart failure preserved ejection fraction (HFpEF) is a clinical syndrome resulting 
from increased resistance in the filling of the left ventricle (LV) leading to symptoms of 
congestion (Yancy et al., 2013) although the exact cause continues to be unknown and the 
identification of markers that predict HFpEF risk have not been proven (Owan et al., 2006; 
Wong et al., 2013).  Data from the National Health and Nutrition Examination Survey 
(NHANES) suggests an estimated 5.1 million Americans >20 years have HF, HFpEF 
accounts for at least 50% of all HF hospital admissions and forecasts a 46% increase in 
HFpEF prevalence by 2030 (AlJaroudi et al., 2012; Heidenreich, Albert, Allen, Bluemke, & 
Trogdon, 2013).  However, biomarkers that enable prevention, diagnostic and treatment 
guidelines and population specific characteristics are not evident in the literature (Gladden et 
al., 2014; Wong et al., 2013; Yancy et al., 2013).   
The pathophysiologic understanding of HF has changed notably over the last 25 years 
(Little & Zile, 2012).  Terminology has evolved to include HF syndromes with ejection 
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fraction (EF) >50% described as diastolic heart failure (DHF) and as the pathophysiological 
mechanisms of HF became clearer the terms were changed to HFpEF and heart failure 
reduced ejection fraction (HFrEF) which are currently used (Little & Zile, 2012).  Although 
the understanding of HFpEF pathophysiology has progressed, definitive research on 
population specific pathophysiology, consistent use of biomarkers and guidelines for 
diagnosis and treatment are not yet established. 
Pathophysiology and Biomarkers of HFpEF 
Because HFpEF is a complex syndrome an integrated approach best explains the 
phenomenon (Gladden et al., 2014).  Multiple aspects of pathophysiology are involved in the 
progression from asymptomatic dysfunction to incident HFpEF and include:  systemic 
inflammation, LV hypertrophy, slow LV relaxation, LV diastolic stiffness, decreased LV 
systolic performance, left atrial remodeling, peripheral vascular resistance, impaired 
epithelial function, increased pulmonary arterial and venous resistance, neurohormonal 
activation and ventricular-arterial coupling (Gladden et al., 2014).   Borlaug and Kass (2011) 
described one possible physiological theory of the progressive maladaptive process in the 
context of ventricular-arterial coupling, defined as LV systolic elastance (Ees) and arterial 
elastance (Ea) (Borlaug & Kass, 2011).  With vascular dysfunction, acute afterload elevation 
combined with ventricular-arterial stiffening contributes to increases in blood pressure 
(Borlaug et al., 2011).  This mechanism then impairs diastolic LV relaxation leading to 
further increases in blood pressure contributing to dramatic increases in LV filling pressures 
during stress thus the adaptive physiologic response evolves to a pathologic response such as 
incident HFpEF (Borlaug, Olson, et al., 2010). 
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Paulus and colleagues (2013) describe HFpEF from the perspective of the pro-
inflammatory effect of multiple co-morbidities such as obesity, diabetes, hypertension and 
chronic kidney disease that factor into the onset of HFpEF (Paulus & Tschope, 2013).  This 
conceptual paradigm shifts emphasis from LV overload excess to including coronary 
microvascular inflammation (Paulus & Tschope, 2013).  From this perspective, comorbidities 
and plasma markers of inflammation should be factored into diagnostic algorithms for 
HFpEF (Paulus & Tschope, 2013). 
Hypertension (HTN) or elevated blood pressure is a well-documented antecedent to 
the development of HF and as many as 90% of HF cases are preceded by the diagnosis of 
HTN (Pickering, 2004).  In the setting of elevated blood pressure, LV and arterial stiffening 
are abnormally elevated in patients with HFpEF (Borlaug & Kass, 2011; Borlaug & Paulus, 
2011).  One application of ventricular/arterial coupling (Ees/Ea) physiology suggests that 
HTN is antecedent to the development of HFpEF (Antonini-Canterin et al., 2013).  In the 
Efficacy in Diastolic Dysfunction (EXCEED) trial, 527 patients with early stage HTN, after 
24-48 weeks of antihypertensive therapy, there was evidence of an increase in the effective 
Ea/Ees ratio (r=-0.25, p<0.01) (Lam et al., 2013).  The impact of antihypertensive treatment 
on patients with HTN and diastolic dysfunction (DD) on the Ea/Ees suggests that blood 
pressure control is one method to prevent the progression of hypertensive heart disease to 
decompensated HFpEF, even in the early stages of disease (Lam et al., 2013). 
Physiology of Diastolic and Systolic Function 
Diastole starts when the aortic valve closes and includes LV pressure fall, rapid 
filling, diastasis and atrial contraction (Brutsaert et al., 1993).  Key aspects of diastolic 
function are:  a) myocardial relaxation and passive LV filling, properties modulated by 
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myocardial tone, b) myocardial relaxation determined by load, and c) myocardial stiffness 
determined by the myocardial cell and interstitial matrix (Nagueh et al., 2009).   
Systole starts when the mitral valve closes and lasts until aortic valve closes (Otto, 
2004).  In terms of ventricular pressure changes, systole begins when LV diastolic pressure 
exceeds left atrial pressure, resulting in closure of the mitral valve, ventricular pressure 
increases, exceeds aortic pressure and the aortic valve opens, ejection occurs, LV volume 
drops and the aortic valve closes (Otto, 2004).  LV systolic function is best described by 
contraction and is affected by heart rate, preload and afterload (Otto, 2004).  
Optimal performance of the LV is dependent upon the ability of heart to cycle two 
states; a) a compliant left ventricle that allows the LV to fill during diastole from low left 
atrial pressures, and b) a firm LV chamber in systole that ejects the stroke volume (volume of 
blood pumped from one ventricle of the heart with each beat) at arterial pressures (Nagueh et 
al., 2009).  In addition, the stroke volume (SV) must accommodate to meet the metabolic 
needs of the body, as with exercise without much increase in left atrial (LA) pressure 
(Brutsaert et al., 1993).   
The 2-D (dimensional), M (motion)-mode Doppler echocardiogram (echo) is the most 
commonly used imaging technique to evaluate diastolic and systolic function in addition to 
evaluating functional abnormalities of the heart muscle, valves and pericardium (Nagueh et 
al., 2009; Yancy et al., 2013).  In describing physiology the term biomarker will be used as 
defined by the National Institute of Health (NIH) as an objective functional or physiologic 
measure of biological, pathological or therapeutic interventions (2001).   
Physiology of Diastolic and Systolic Dysfunction 
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The two main mechanisms involved in diastolic dysfunction (DD) are abnormal 
relaxation and passive stiffness (decreased compliance of the LV) that manifests as 
prolonged isovolumetric relaxation, slow LV filling and increased diastolic stiffness 
(Braunwald & Zipes, 2001; Libby, 2008).  Cardiac relaxation is dependent upon calcium 
(Ca2+) reuptake and elastic recoil related directly to the sarcoplasmic reticulum Ca2 ATPase 
pump (Gladden et al., 2014).  The primary biomarkers of diastolic function are mitral inflow 
that include peak early filling (E-wave) and late diastolic filling (A-wave) velocities, the E/A 
ratio reflects grade of diastolic dysfunction (DD), (Nagueh et al., 2009).  Different DD grades 
suggest varying levels of dysfunction and are reflected by the following parameters (Nagueh 
et al., 2009)  Please see Appendix A. for a complete list of all abbreviations. 
Based on diagnostic guidelines from the European Society of Cardiology (ESC), in 
addition to clinical symptoms, early mitral valve annular velocity (E’), and the ratio of E 
(early ventricular filling)/e’(early mitral valve annular velocity) are important in estimating 
LV filling pressures (Nagueh et al., 2009).  Evidence of E/e’>15 is diagnostic of LV DD and 
E/e’<8 is diagnostic of absence of HFpEF and E/E’ ranges from 8-15 are suggestive of LV 
DD that require further evaluation with biomarkers such as E/A ratio or brain natriuretic 
peptide BNP (Paulus et al., 2007). 
In previous studies evaluating potential causes of HFpEF, DD (diastolic dysfunction 
grade 1, 2 or 3/4) was considered a primary antecedent to HFpEF (Hanrath et al., 1980).  
HFpEF was commonly thought to represent a process of maladaptive age and HTN related 
remodeling which resulted in DD (Dunlay et al., 2012).  However, with the progression of 
Doppler echo imaging and new science describing physiology, evidence of DD was found to 
be one of several factors that impact the development of HFpEF (Borlaug & Paulus, 2011).  
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Reasons to consider an integrated physiology approach to HFpEF include the multiple other 
factors with important mechanisms underlying HFpEF, such as: stiff cardiomyocytes and 
fibrosis, resting and exercise systolic dysfunction, impaired ventricular-arterial coupling, 
chronotropic incompetence (Borlaug, Olson, et al., 2010; Dunlay et al., 2012) endothelial 
dysfunction, microvascular CAD (Borlaug & Paulus, 2011) and pulmonary arterial 
hypertension (Lam et al., 2009).  Therefore DD likely plays a key role in the cause of 
symptoms in HFpEF however, DD is not necessarily required to produce HFpEF (Redfield et 
al., 2003).   
The primary measurements of systolic function are measures of contractility that 
include EF, cardiac output (CO) and stroke volume (SV) (Otto, 2004).  Global cardiac 
function is most commonly assessed with echo by measuring the EF (Otto, 2004).  EF is 
directly calculated from ventricular volumes and is load dependent, rather than a true 
measure of cardiac contractility (Braunwald & Zipes, 2001).  Although EF may not 
consistently be a valid or reliable estimate of true myocardial contractility, it is the most 
commonly used method for assessing LV function (Feigenbaum et al., 2005).  As a result, 
myocardial EF is used as an important classification in distinguishing patient demographics, 
co-morbid conditions, prognosis and treatment (Yancy et al., 2013).  It is recognized that 
most HF patients may have varying degrees of systolic and diastolic LV abnormalities not 
reflected in the EF (Borlaug & Paulus, 2011).   
Evidence of decreased exercise reserve is likely the first sign of early HFpEF 
(Gladden et al., 2014).  Both systolic and diastolic reserve are impaired with HFpEF and 
exercise may reveal the mild defects (Borlaug & Paulus, 2011).  One theory that explains the 
impairment of cardiac reserve is related to ventricular-arterial stiffness.  As stiffness 
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increases, wide pressure swings occur that interfere with flow and worsen pressure (Borlaug 
& Kass, 2011)  The increase in pressure results in greater work requiring greater oxygen 
consumption, this increase in work-load results in impaired reserve, labile BP, decreased 
coronary flow and increased diastolic filling pressures (Borlaug & Kass, 2011).  In addition, 
exertional intolerance is common with HFpEF due to elevated filling pressures reflected in 
elevated E/E’ (Gladden et al., 2014).  Many patients have exercise intolerance without 
evidence of volume overload (Borlaug & Paulus, 2011).  Pulmonary artery pressures 
correlate closely with left heart filling pressures in early stage HFpEF (Borlaug, Nishimura, 
Sorajja, Lam, & Redfield, 2010), therefore tracking pulmonary pressures (PCWP>12mmHg 
and LVEDP>16mmHg) with echo may be an optimum screening tool in detecting early 
HFpEF in patients with normal EF and exertional dyspnea (Borlaug & Paulus, 2011).  
As a measure of systolic function, contractility is more accurately represented by 
ventricular-arterial coupling versus ejection fraction alone suggesting that EF does not reflect 
all aspects of LV contractility (Borlaug & Paulus, 2011).  The impact of ventricular-arterial 
coupling, (Ees) to effective arterial elastance (Ea) likely has a key role in understanding the 
pathogenesis of HFpEF (Borlaug & Redfield, 2011).  In the context of ventricular-arterial 
coupling and vascular dysfunction, acute afterload elevation combined with ventricular-
arterial stiffening contributes to increases in blood pressure (Borlaug & Paulus, 2011).  In the 
setting of HFpEF, systemic vasorelaxation during exercise is diminished, impairing blood 
flow to skeletal muscle (Borlaug, Olson, et al., 2010; Borlaug & Paulus, 2011).  Patients with 
HFpEF have systolic-ventricular and arterial stiffening beyond that associated with aging 
and/or HTN and is attributed to stress (Kawaguchi, Hay, Fetics, & Kass, 2003).  Elevated 
Ees/Ea likely exacerbates the HTN stress response by delaying relaxation, limiting filling and 
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raising diastolic pressures (Kawaguchi et al., 2003), although EF is maintained (Gladden et 
al., 2014).  Lam and colleagues (2013) demonstrate that blood pressure control decreases 
measures of arterial stiffness and ventricular arterial coupling and acts to prevent HFpEF, 
however, once HFpEF occurs, antihypertensive medications have not significantly altered 
HFpEF death outcomes (Gladden et al., 2014). 
The single beat method of measuring ventricular elastance (Ees) has been validated 
against invasive hemodynamic measurement of LV performance (Borlaug & Kass, 2009; 
Borlaug et al., 2009; Chen et al., 2001; Ky et al., 2013).  Both measures; Ees and Ea are 
expressed in mmHg/ml and therefore comparable mathematically in a ratio.  Normal Ea and 
Ees values in resting subjects are 2.2 ± 0.8 mmHg/ml and 2.3 ± 1.0 mmHg/ml, respectively, 
and when the Ea/Ees ratio is 0.5-1.0, this suggests optimal function, but when the ratio is 
>1.0, this suggests that the LV becomes progressively less efficient (Antonini-Canterin et al., 
2013; Borlaug et al., 2009).   
The following is the single beat formulae used to calculate Ees(sb) (Chen et al., 
2001):  
Ees=(DBP − (E nd(est) × SBP × 0.9))/E nd(est) × SV -  with the E nd(est)=estimated normalized 
ventricular elastance at the onset of ejection, SV=Doppler derived stroke volume (Chen et al., 
2001).   
The following formulae is used to calculate arterial afterload (Ea):  
Ea=0.9 x ESP (brachial systolic pressure (mmHg)/SV with SV=Doppler derived stroke 
volume (Borlaug & Kass, 2011). 
One of the main applications is the Ea/Ees physiology is the application to HTN as a 
determinant of HF (Antonini-Canterin et al., 2013).  In the setting of elevated blood pressure, 
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Ees/Ea are abnormally elevated in patients with HFpEF (Borlaug & Paulus, 2011).  Also in 
the Efficacy in Diastolic Dysfunction (EXCEED) trial, the impact of antihypertensive 
treatment on patients with HTN and DD on the Ees/Ea ratio suggested that blood pressure 
control may be one way to prevent progression of hypertensive heart disease to 
decompensated HFpEF, even in the early stages of disease (Lam et al., 2013).  In addition, 
studies have confirmed that Ees is increased in the setting of impaired myocardial 
contractility (systole) suggesting a reduction in myocardial contractility (Borlaug & Paulus, 
2011).  This is an important pathophysiological finding given that reduced myocardial 
contractility has been associated with increased mortality (Borlaug et al., 2009). 
Also measured by echo, another marker of LV contractility is strain rate imaging.  
Specifically global longitudinal strain (GLS) has been shown to have diagnostic and 
predictive morbidity/mortality benefit in studying HFpEF superior to measurement of EF.  
GLS has been closely coupled with evaluating diastolic function, acute decompensated 
HFpEF, acute MI and evaluating reduced exercise capacity in HFpEF patients (Ersboll et al., 
2013; Hasselberg et al., 2015; Yoon et al., 2014).   
In addition to echo, cardiac magnetic resonance imaging (cMRI) has demonstrated 
utility in detecting functional abnormalities for both diastolic and systolic dysfunction and 
especially myocardial fibrosis (Borlaug & Paulus, 2011; Mewton, Liu, Croisille, Bluemke, & 
Lima, 2011).  However the finding of fibrosis on cMRI is not an early finding of HFpEF and 
may not be specific to HFpEF (Desai et al., 2014). 
Neurohormonal activation has not been extensively studied in HFpEF but limited 
evaluation suggests activation of the adrenergic and renin-angiotensin-aldosterone system 
(RAAS) contributes to progressive remodeling and contractile dysfunction (Dunlay et al., 
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2012).  Given that HTN, specifically systolic HTN, is present in most patients with HFpEF it 
strengthens the hypothesis that activation of the RAAS is a unifying concept in the genesis of 
HFpEF (Gladden et al., 2014; Steinberg et al., 2012).  Given the high associated comorbidity 
of chronic kidney disease associated with HFpEF, this further supports that multiple systems 
are involves in the genesis of this syndrome (Paulus & Tschope, 2013). 
Cardiac arrhythmia, specifically atrial fibrillation associated with left atrial 
remodeling may be a marker for HFpEF.  The left atrium is typically enlarged with HFpEF 
and the degree of enlargement may be a rough estimate of the chronicity of HFpEF 
(Melenovsky et al., 2007).  Structural remodeling of the LA leads to electrical remodeling 
which predisposes HFpEF patients to atrial fibrillation (AF) (70% of patients with HFpEF 
have AF) (Zakeri, Chamberlain, Roger, & Redfield, 2013).  It is unclear if AF is a marker of 
more advanced LV dysfunction or contributor to the pathophysiology (loss of atrial-
ventricular synchrony, irregular heart rate, impaired LA compliance) associated with HFpEF 
(Gladden et al., 2014).   
Guidelines for HFpEF Diagnosis 
HFpEF is typically characterized by EF>50% (Borlaug & Paulus, 2011).  Four sets of 
diagnostic criteria for the diagnosis of HFpEF have so far been published, including the 
ACCF/ACC HF Guidelines for the Management of Heart Failure ("How to diagnose diastolic 
heart failure. European Study Group on Diastolic Heart Failure," 1998; Paulus et al., 2007; 
Vasan & Levy, 2000; Yturralde & Gaasch, 2005).  All of the HFpEF guidelines require the 
presence of signs or symptoms of HF, evidence of normal systolic LV function, evidence of 
diastolic dysfunction or surrogate markers that include LV hypertrophy, LA enlargement, 
atrial fibrillation or elevated BNP levels (Paulus et al., 2007).  None of the guidelines have 
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been validated (Borlaug & Paulus, 2011).  The first set came from the Working Group on 
Myocardial Function of the European Society of Cardiology ("How to diagnose diastolic 
heart failure. European Study Group on Diastolic Heart Failure," 1998).  The second set 
came from the National Heart Lung Blood Institute Framingham Heart Study in which 
invasive evidence of diastolic dysfunction was required (Vasan & Levy, 2000).  The third set 
came from the Lahey Clinic where a scoring system was designed along with surrogate 
markers for DD by LVH and left atrial enlargement (Yturralde & Gaasch, 2005).  The fourth 
set of guidelines was initially published in 1998 by the European Society of Cardiology 
(ESC) and then was revised in 2007 including signs and symptoms of HF, LVEF >50%, 
evidence of DD (elevated left ventricular end diastolic pressure (LVEDP)>16mmHg, 
pulmonary capillary wedge pressure>12mmHg, E/E’>15, mitral flow velocity Doppler signal 
showing E/A ratio<0.5+deceleration time (DT) >280ms, LA size>40mL/m2, or LV 
mass>149g/m2-men or >122g/m2-women (Paulus et al., 2007).  The ACCF/ACC 2013 HF 
Guidelines for the Management of Heart Failure published a chart (Table 1) with HFpEF 
definitions (Yancy et al., 2013), however a specific endorsement of HFpEF diagnostic 
criteria was not suggested.   
The most commonly referenced diagnostic HF criterion is the Framingham criteria.  
The Framingham criteria was published by McKey et al., in 1971 to describe symptoms 
suggestive of congestive heart failure and requires that major and minor clinical symptoms 
be present such as paroxysmal nocturnal dyspnea, neck vein distention or acute pulmonary 
edema (there are 16 possible symptoms (McKee, Castelli, McNamara, & Kannel, 1971).  
Although the Framingham criteria is the most commonly used criteria for HF diagnosis, 
25 
 
biomarkers are not incorporated into the Framingham criteria and the criteria is not specific 
to HFpEF. 
HFpEF Treatment 
Pharmacologic trials including ace inhibitors, ARBs, β-blockers, statins and 
aldosterone antagonists and the consideration of electrophysiology trials have all been 
evaluated in the treatment of HFpEF.  Pharmacologic treatments for HFpEF typically 
manage symptoms and have otherwise been ineffective in showing benefit (Yancy et al., 
2013) with the exceptions of one trial evaluating statins and a post hoc analysis of a second 
trial that showed benefit with aldosterone-antagonist (Fukuta, Sane, Brucks, & Little, 2005; 
Pfeffer et al., 2015).  Details of each treatment option for HFpEF are detailed in the 
following summary. 
Ace1-inhibitors/ARBs.  The effect of ace inhibitors and ARBs on HF is not 
completely understood and likely has mechanistic properties that include more than 
decreasing preload and afterload (Haywood et al., 1997).  The perindopril in elderly people 
with chronic heart failure (PEP-CHF) trial was the first prospective randomized trial that 
evaluated ace inhibitors in HFpEF patients (Cleland et al., 2006).  The study evaluated 850 
patients with EF>40%, and >70 years of age on perindopril 4mg daily (Cleland et al., 2006).  
The trial was insufficiently powered to meet the primary endpoint of morbidity and mortality 
but patients on treatment reported improved symptoms, exercise capacity (p=0.011) and 
fewer hospitalizations (p=0.033) in the first year on therapy (Cleland et al., 2006).  In the 
Candesartan in Heart failure:  Assessment of Reduction in Mortality and Morbidity 
(CHARM)-Preserved Trial, an ARB was evaluated in HFpEF patients on the effect on 
mortality and re-hospitalization (Yusuf et al., 2003).  The study evaluated 3023 patients with 
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EF>40% Candesartan 32mg daily, and reduced hospitalizations (p=0.017) but showed no 
difference in mortality (p=0.118) (Yusuf et al., 2003).  In the Irbesartan in Heart Failure with 
Preserved Ejection Fraction Study (I-PRESERVE) trial an ARB was evaluated in HFpEF 
patients on the effect on mortality, hospitalization and quality of life (Massie et al., 2008).  
This study evaluated 4128 patients with EF>45% and >60 years of age with findings that that 
irbesartan did not improve outcomes in patients with HFpEF (Massie et al., 2008).  With 
HFpEF, both LV and arterial elastance are increased suggesting the LV and arterial system 
are functioning at maximum capacity (stretched) which explains why arterial vasodilatation 
(ace inhibitors) work with HFrEF but not with HFpEF (Borlaug & Paulus, 2011; 
Schwartzenberg et al., 2012).   
Beta-blockers.  Traditionally β-blockers have been recommended for the treatment of 
HFpEF for the negative chronotropic (decrease heart rate) effect to increase the diastolic 
filling period (Borlaug & Paulus, 2011).  However studies have shown that chronotropic 
incompetence is highly prevalent in HFpEF and use of β-blockers in the absence of 
tachycardia decreases exercise capacity (Borlaug, Nishimura, et al., 2010).  In the Organized 
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure 
(OPTIMIZE-HF) registry, the use of β-blockers was evaluated in HFpEF and HFrEF patients 
(Hernandez et al., 2009).  The study evaluated 7154 hospitalized patients, >72years of age, 
with HF and divided EF <30%, 30-39%, 40-49% and >50% and showed that β-blockers had 
no effect on 1 year mortality or hospitalization rates in HFpEF patients but significantly 
improved both endpoints in the HFrEF group (Hernandez et al., 2009).   
Statins.  The effect of statin therapy (Hydroxymethylglutaryl coenzyme A – (HMG 
Co-A) reductase inhibitors) for patients with HFpEF statins may have a role with ventricular 
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remodeling (Indolfi et al., 2002), sympathetic nervous system activation (Pliquett, Cornish, 
Peuler, & Zucker, 2003), inflammation (Rauchhaus, Coats, & Anker, 2000) and endothelial 
function (Bates, Ruggeroli, Goldman, & Gaballa, 2002).  Fukuta and colleagues studied the 
mortality effect of statin therapy on 185 HFpEF patients with EF>50%, on statin 
(atorvastatin, mean dose 22mg, simvastatin mean dose 37mg, pravastatin mean dose 30mg, 
fluvastatin mean dose 80mg daily) and showed a statistically significant (p=0.013) reduction 
in mortality in patients with HFpEF on mortality (Fukuta et al., 2005).  The cause remains 
unclear but may be related to microvascular myocardial ischemia (50% of HFpEF patients 
have a diagnosis of CAD) (Chattopadhyay et al., 2010) (Mohammed et al., 2014), impaired 
β-adrenergic signaling (Phan et al., 2009), or abnormal calcium handling (Liu et al., 1993).  
Observational studies have demonstrated better outcomes in HFpEF patients treated with 
statins however it is unclear if this is due to the effect on CAD progression or decrease in 
endothelial inflammation (Paulus & Tschope, 2013).  To date studies have not been 
conducted to evaluate microvascular chronic ischemia as a cause of HFpEF (Hoenig, 
Bianchi, Rosenzweig, & Sellke, 2008).   
Aldosterone-antagonists.  Aldosterone and the pathogenesis of vascular stiffening and 
endothelial dysfunction has been studied in both HFpEF and HFrEF (Weber, 2001).  In the 
Treatment of Preserved Cardiac Function in Heart Failure with an Aldosterone Antagonist 
(TOPCAT) trial, spironolactone titrated up to 45mg daily was studied in HFpEF patients for 
the effect on mortality and hospitalization rate (Pitt et al., 2014).  This international study 
conducted in 6 countries that included Russia and Georgia, United States, Canada, Argentina 
and Brazil evaluated 3445 patients with EF>45% and >50 years of age, randomized to either 
spironolactone or placebo and used the Framingham criteria to define HFpEF.  The initial 
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results did not suggest statistical significance in mortality benefit (p=0.14) but did show 
benefit in reducing hospitalizations (p=0.04), (Pitt et al., 2014).  However, post hoc analysis 
of TOPCAT suggested regional variation in the Americas with statistically significant benefit 
in both mortality and hospitalization with a hazard ratio for treatment with spironolactone 
with respect to cardiovascular death 0.74 (95% CI, 0.57–0.97), and hazard ratio for heart 
failure hospitalization with spironolactone treatment was 0.82 (95% CI, 0.67–0.99) (Pfeffer 
et al., 2015).  Inconsistencies in HFpEF diagnostic criteria in Russia and Georgia have been 
referenced as the cause of mortality insignificance with the initial reporting of TOPCAT 
(Pfeffer et al., 2015). 
Calcium Channel Blockers.  Experimental investigations with a selective calcium 
channel inhibitor ivabradine have demonstrated benefit with short term treatment (Kosmala 
et al., 2013).  Tested in prospective trial of 30 patients in the placebo group and 30 patients 
treated twice daily for 7 days with ivabradine.  The treatment group showed improved 
exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake 
(14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001).  This benefit may be explained 
by improved diastolic filling as a result of the rate slowing effect and improved myocardial 
relaxation (Kosmala et al., 2013).  To date, evidence is lacking to support longer term 
treatment with ivabradine.   
Electrophysiology.  Although chronotropic incompetence is found in patients with 
incident HFpEF, a therapeutic indication for cardiac pacing in HFpEF patients has not been 
established (Borlaug & Paulus, 2011).  Atrial fibrillation is common with HFpEF but 
treatment is focused on AF management not the underlying pathophysiology (Zakeri et al., 
2013).   
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Exercise.  Exercise training in HFpEF has shown benefit in improving exercise 
tolerance and managing obesity (Taylor et al., 2012).  IN the HF-Action trial, O’Connor and 
colleagues demonstrated that exercise had a modest reduction for both all-cause mortality 
and re-hospitalization but was focused on HFrEF patients (O'Connor et al., 2009).  In a meta-
analysis of exercise training in HFpEF, findings suggest that exercise training was associated 
with a fold improvement in cardiovascular fitness 2.72 (CI 1.79-3.65), and 4 fold increase in 
quality of life, 3.97 (CI -7.21, -0.72) and non-significant changes in LV systolic or diastolic 
function, 1.26 (CI -0.13, 2.66), 0.08 (CI -0.01-0.16) (Pandey et al., 2015).  Interestingly, this 
study used EF and diastolic parameters (such as diastolic grade) as the primary measures of 
systolic and diastolic function. 
Population Stratification:  Age Race and Sex as Key Attributes 
Controversy exists in the scientific literature on the description of patient populations 
most commonly affected by incident HFpEF.  The ACCF/AHA guidelines suggest that 
White women, >65 years of age with a history of HTN are most commonly affected by 
HFpEF (Crowder, Irons, Meyerrose, & Seifert, 2010; Yancy et al., 2013).  However, studies 
with a racially diverse sample that included subjects <65 years of age, indicate Black women 
are most commonly affected by incident HFpEF (Desai et al., 2013; Wong et al., 2013).  
Given that at least 90% of HFpEF cases are preceded by a diagnosis of HTN (Pickering, 
2004) and that Black patients had twice the incidence of new HTN compared to White 
patients over a 10 year period (Egan, Zhao, & Axon, 2010; Ford & Cooper, 1991; Gillum, 
1991) more definitive exploration of race and age in future HFpEF is indicated. 
In a trial evaluating the relationship of race to HFpEF incidence and outcomes, 
13,437 adults with HFpEF from 2005 to 2008 from four regionally different health systems 
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within the U.S. were suggested that Blacks had a 48% higher risk of hospitalization 
compared to Whites and Asians and with patients <65 years of age and that incident HF 
admission occurred more commonly in Blacks compared to Whites and Asians (Gurwitz et 
al., 2014).  Also the prevalence of HF among different ethnic and racial groups is expected to 
increase substantially (Al-Dubai, Alshagga, Rampal, & Sulaiman, 2012) with the highest 
prevalence to be among Black patients increasing by 29% between 2012 and 2030, from 
2.8% to 3.6% of the Black population (Heidenreich et al., 2013), followed by Hispanic, 
White, and Chinese (Bild et al., 2005).  In addition to alarming trends in incidence and 
prevalence, mortality data suggest a 34% higher five year mortality rate for Blacks with 
HFpEF compared to White patients (East, Peterson, Shaw, Gattis, & O'Connor, 2004) 
Conclusions 
HFpEF is a complex clinical syndrome with increasingly significant health and fiscal 
implications (Gladden et al., 2014).  Multiple co-morbidities and the associated pro-
inflammatory state contribute to the onset of HFPEF (Paulus & Tschope, 2013).  Although 
this syndrome is not limited to a problem of LV contractility, the use of Ea and Ees to reflect 
arterial-ventricular coupling have demonstrated physiologic utility in studying the 
phenomenon of HFpEF (Borlaug & Paulus, 2011).  In addition to the complexity of 
pathophysiology, diagnostic guidelines for HFpEF are not consistently used.  In the 
TOPCAT trial the study initially reported non-significant mortality findings; however, post 
hoc analysis stated ‘regional variation’ in the Americas and re-analysis did show mortality 
benefit (Pitt et al., 2014).  In TOPCAT the diagnostic criteria used for inclusion was the 
Framingham HF criteria which is not specific to HFpEF and does not include biomarkers in 
making the diagnosis (only clinical findings).  Although study of the etiology of HFpEF is 
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evolving and the exact cause remains unclear, without consistent use of current diagnostic 
criteria in studying HFpEF, more confusion in defining this heterogeneous population is 
likely to result.  
This review outlines the pathophysiology of current and novel biomarkers and 
consideration of the pro-inflammatory effect of multiple co-morbidities, demonstrates the 
infrequent use of diagnostic criteria and emphasizes the importance of implementing a 
diverse study sample.   Incorporating each component (diagnosis, biomarkers, co-
morbidities, representative population) into comparisons between adults with and without 
HFpEF over time would greatly contribute to our current scientific knowledge base.  In 
summary, consistent use of HFPEF diagnostic criteria with standardized measures of 
biomarkers, studied overtime, are areas requiring further exploration.   
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CHAPTER 3 
 
PAPER 2: COMPARING NOVEL BIOMARKERS ASSOCIATED WITH HEART 
FAILURE PRESERVED EJECTION FRACTION (HFpEF):  A MATCHED CASE-
CONTROL ANALYSIS 
 
 
Overview 
 
Objectives: 
This study was designed to detect differences in biomarkers associated with incident heart 
failure preserved ejection fraction (HFpEF) when comparing matched case-control groups.    
Background: 
Evidence continues to demonstrate increasing prevalence, cost and mortality implications of 
HFpEF.  Early identification of biomarkers associated with incident HFpEF would contribute 
greatly to the current science.  
Methods: 
A study cohort of 310 patients, that included case (incident HFpEF patients, n=155) and 
matched control (patients with no prior HF, n=155) groups were retrospectively identified.  
Matching criteria included race, sex, age (within 3 years) and previously acquired 
echocardiogram biomarkers (within 1year).  Physiologic and echocardiogram biomarkers 
were collected from previously acquired 2-D (dimensional) M-mode Doppler 
echocardiograms.  Echo images were re-analyzed from previously obtained echo to calculate 
measures factored into calculating ventricular-arterial coupling.  To estimate ventricular 
elastance, the single beat method was used.  Covariates and model fit were tested.  Using 
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conditional logistic regression and controlling for covariates, models were fit to detect 
differences in HFpEF biomarkers between the matched case-control groups. 
Results: 
Statistically significant differences in biomarkers that reflect ventricular elastance (Ees) 
(p=0.0030) and left atrial diameter (LAdiam) (p=0.0002) were detected when comparing the 
case and control groups.  Conditional logistic regression analyses suggested a 30% higher 
odds of converting to the case group with every 1 unit increase in Ees, OR 1.315 (1.097, 
1.575) and a 4.57 times higher odds of being in the case group for every 1 unit increase in 
LAdiam, OR 4.565 (2.038, 10.223).   
Conclusions 
Ees and LAdiam may have a role in tracking physiology as it relates to HFpEF.  This study 
demonstrates that it is feasible to calculate both the Ees and LAdiam from routinely obtained 
echo images without increasing cost or risk.  Prospective studies are indicated that explore 
the use of Ees and LAdiam as predictors of impending HFpEF.  
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PAPER 2: COMPARING NOVEL BIOMARKERS ASSOCIATED WITH HEART 
FAILURE PRESERVED EJECTION FRACTION (HFpEF):  A MATCHED CASE-
CONTROL ANALYSIS 
 
Objective 
 This manuscript presents the findings of a matched case-control study.  The case 
group consisted of patients previously discharged with incident (first case) heart failure 
preserved ejection fraction (HFpEF).  The control group consisted of patients with no prior 
history of heart failure (HF).  Groups were matched based on age, race, sex and date of 
echocardiogram.  This paper includes an analysis of differences within the matched cohorts 
comparing physiologic and echocardiographic biomarkers. 
Background 
Heart failure preserved ejection fraction (HFpEF) accounts for at least 50% of all 
hospital admissions for heart failure (HF) in the United States (U.S.) yet measures that 
predict risk and onset of HFpEF are lacking (Gladden et al., 2014; Heidenreich et al., 2013).  
HFpEF is a heterogeneous syndrome likely affected by multiple comorbidities with 
inflammatory precursors (Lam et al., 2011; Paulus & Tschope, 2013).  Clinical diagnosis is 
typically based on patient history and physical examination; however, epidemiologic studies 
suggest that some patients are asymptomatic but have evidence of abnormal biomarkers such 
as diastolic dysfunction (Owan & Redfield, 2005; Yancy et al., 2013).  The relative risk 
associated with specific biomarkers (Ky et al., 2013) and the impact of age, gender and race 
have not been established (Shah, 2012).  Therefore, studies that include samples stratified by 
age, race and sex that identify biomarkers that predict impending HFpEF may help identify 
targets for larger samples over time. 
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Previous studies predicting risk or outcomes in HFpEF patients, most of which 
compared HFpEF and HFrEF groups to control groups and some of which matched on age 
and gender, suggested utility in echo biomarkers that include measurement of left ventricular 
hypertrophy (LVH), estimates of left ventricular filling (E/e’), left atrial (LA) size, global 
longitudinal strain (GLS), arterial elastance (Ea), ventricular elastance (Ees) and ventricular-
arterial coupling (Borlaug et al., 2009; Mohammed et al., 2012; Shuai et al., 2011; Stampehl 
et al., 2015).  However, none of the studies included race in the matched groups.  In addition, 
the pathophysiology of HFpEF is complex reflected by LV hypertrophy, pro-inflammatory 
markers, slow LV relaxation, LV diastolic stiffness, decreased LV systolic performance, left 
atrial remodeling, peripheral vascular resistance, impaired epithelial function, increased 
pulmonary arterial and venous resistance, neurohormonal activation and mismatched 
ventricular-arterial coupling (Gladden et al., 2014; Paulus & Tschope, 2013). 
LV ejection fraction (EF) is an important volumetric measure and predictor of 
outcome, however, EF does not incorporate load, contractility and the interaction of 
ventricular-arterial stiffening (Borlaug et al., 2009).  Non-invasive measures have been 
established such as LV systolic elastance (Ees)(mmHg/ml) which incorporates measures of 
LV end-diastolic volume (EDV), LV size and cardiac remodeling and the end-systolic 
pressure volume relationship (ESPVR) which is a load-dependent measure of contractile 
function (Ky et al., 2013).  Arterial elastance (Ea)(mmHg/ml) is a measure that incorporates 
end-systolic pressure (ESP) and end-diastolic volume to incorporate stroke volume (SV), 
therefore Ea=ESP/SV (Ky et al., 2013).  The net interaction of the ventricular and arterial 
systems is measured by Ea/Ees which significantly impacts cardiac performance (Borlaug & 
Kass, 2009, 2011).   
36 
 
Previous studies suggest that optimal ventricular-arterial functioning is reflected in an 
Ea/Ees ratio of 0.5-1.0 which is maintained with normal aging but reportedly declines in 
women because of ventricular stiffening increases out of proportion to vascular load (Borlaug 
et al., 2009; Kawaguchi et al., 2003).  However, studies that evaluate Ea, Ees and Ea/Ees and 
incorporate a diverse range of age, race and gender into the study design have not been 
completed to date.  Ea (arterial elastance) and Ees (ventricular elastance) are measures that 
reflect the interaction of ventricular-arterial coupling.  Therefore in order to better understand 
the phenotype of HFpEF, collecting data on Ea, Ees in addition to stratifying the study group 
by age, race and sex are greatly needed.  For a complete list of all abbreviations used in this 
study, please refer to Appendix A. 
Methods 
Design 
The study was observational with a retrospective matched case-control design.  The 
procedure of case-control group selection began with the consideration of key 
methodological principles in control group selection (Wacholder, Silverman, McLaughlin, & 
Mandel, 1992a).  This framework includes three principles to maximize comparability 
between case-control.  The concepts include compariability of: a) study base, b) 
deconfounding, and c) comparative accuracy (Wacholder, McLaughlin, Silverman, & 
Mandel, 1992).  To control the study base, for both the case and control groups, the study 
samples only included residents of Durham County, North Carolina.  Given that the selected 
academic institution is a regional, national and international referral instituion, selecting only 
residents of Durham County helped control; a) socioeconomic, b) racial and c) access to 
medical care variables, which preserved both the heterogeneity and the homogeniety of the 
study sample.  To further control the study base, only previously completed 2-D 
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(dimensional) M (motion)-mode Doppler echocardiograms, ordered within the health system, 
read at a core laboratory that is certified, regulated and adhered to standards set by the 
American Society of Echocardiography (ASE) (Wang & Nagueh, 2009) on patients that met 
the inclusion and exclusion criteria, were eligible for this study. 
The case group only included patients with an incident (first) HFpEF hospital 
admission and the control group only included patients with no history of incident HFpEF (or 
any type of HF) hospital admission.  Matching on the variables age, race and sex also helped 
reduce the effects of confounding variables (Wacholder, Silverman, McLaughlin, & Mandel, 
1992b).   
To maximize comparable accuracy, this study included data extracted from 
previously obtained (derived) data with the exception of echo image measurements for 
ventricular-arterial coupling.  For the coupling variables, two nationally certified echo 
sonographers obtained measures of the LV outflow tract diameter at the pulse wave Doppler 
signal and measures of the flow onset time and end time from the LVOT waveform.  For 
both the case and control groups, all echos had previously been ordered, interpreted and 
reported based on standards created by the ASE (Wang & Nagueh, 2009) and thus favorably 
contributed to the validity of group to group comparisons. 
Sample and Setting 
Based on power analysis, the number of matched pairs required for this study was 
n=90 or a total of 180 subjects.  Patients in both the case and control groups were required to 
be 18 years of age or older.  All study data were extracted from pre-existing electronic 
sources that included a storage data base, medical record, echocardiogram database and 
imaging database.  In the medical record, race was a self-reported datapoint that was 
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collected from the storage data base and obtained for this study by electronic query.  Self 
reporting of race most accurately reflects the group (Geronimus, Hicken, Keene, & Bound, 
2006).  To prevent racial under-representation from occurring in this study, an a priori 
objective of a racially representative study group relative to the geographic location was 
operationalized into the study design.  Based on 2012 U.S. Census Data, in Durham County 
the general population is 38% White, 41% Black and 14% Hispanic (Commerce, 2012). 
Case Group.  The case group consists of inpatients discharged from a large academic 
medical center in North Carolina from January 1, 2007 thru January 1, 2014 with a primary 
discharge diagnosis of HFpEF for the incident HFpEF admission based on coding of the 
International Classification of Diseases, 9
th
 revision, Clinical Modification (ICD-9_CM) code 
book with codes for 428.30 (diastolic heart failure, unspecified), 428.31 (acute diastolic heart 
failure), 428.32 (chronic diastolic heart failure), 428.33 (acute on chronic diastolic heart 
failure).  Incident HFpEF diagnosis was verified by the reviewer based on the European 
Society of Cardiology (ESC) diagnostic criteria for HFpEF (Paulus et al., 2007), required to 
have at least 1 echo completed one month prior to hospitalization.  The ESC diagnostic 
criteria for HFpEF, described as heart failure normal ejection fraction (HFNEF) is one of 
four published criteria, however, the ESC guide is the only document that incorporates 
clinical symptoms and echo markers into the diagnostic guideline without using invasive 
measures.  Specificially, the ESC diagnostic criteria require clinical signs and symptoms of 
HF (dyspnea, fluid overload or congestion), LVEF >50%, evidence of diastolic dysfunction 
(DD) (elevated left ventricular end diastolic pressure (LVEDP)>16mmHg, pulmonary 
capillary wedge pressure (PCWP)>12mmHg, E/E’>15, mitral flow velocity Doppler signal 
showing early ventricular filling (E)/ late diastolic filling (A) ratio<0.5+deceleration time 
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(DT) >280ms, LA size>40mL/m2, or LV mass>149g/m2-men or >122g/m2-women (Paulus 
et al., 2007).   
Patients were excluded from the case group if chart review as far back as 1995, 
indicated prior HF hospitalization for either HFpEF or heart failure reduced ejection fraction 
(HFrEF), prior echo ejection fraction (EF)<50%, if diastolic function, pulse wave (PW) or 
LV outflow tract (LVOT) imaging could not be obtained from the echocardiogram, presence 
of severe moderate/severe mitral valve disease, history of aortic or mitral valve surgery or 
vegetation, heart transplantation, hypertrophic obstructive cardiomyopathy, persistent 
tachycardia due to chronic atrial fibrillation, congenital heart disease, severe pulmonary 
arterial hypertension (not due to diastolic dysfunction), connective tissue disorders such as 
rheumatoid arthritis, advanced malignancy, shock. 
Control Group.  The control group patients were identified by previously completed 
medical evaluation based on ICD-9 codes for shortness of breath (786.05) at Duke University 
from January 1, 2007-January 1, 2014 through an electronic query of a data repository.  This 
time period was selected because echo protocols and imaging improved in 2007.  Criteria set 
for inclusion were age >18years, Durham County zip codes, ICD-9 code for shortness of 
breath (ICD-9 code 786.05) presenting either through the emergency department or to an 
outpatient clinic for evaluation and management of shortness of breath.  Patients were 
matched one to one to the case group based on age (3 years or less), race, sex and a record of 
at least 1 echocardiogram completed within 1 year of the matched case.  Controls had no 
prior hospital admissions for HF, no prior evidence of LV dysfunction based on ICD-9 codes, 
and the individual medical records of each patient were reviewed to confirm no prior HFpEF, 
HF history or echo evidence of LV dysfunction.   
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Exclusion Criteria.  Patients were excluded if chart review indicated prior HF 
hospitalization for either HFpEF or heart failure reduced ejection fraction (HFrEF), prior 
echo ejection fraction (EF)<50%, if diastolic function, pulse wave or LV outflow tract image 
could not be measured from the echocardiogram, presence of severe moderate/severe mitral 
valve disease, history of aortic or mitral valve surgery or vegetation, heart transplantation, 
hypertrophic obstructive cardiomyopathy, persistent tachycardia due to chronic atrial 
fibrillation, congenital heart disease, severe pulmonary arterial hypertension (not due to 
diastolic dysfunction), connective tissue disorders such as rheumatoid arthritis, shock or 
advanced malignancy. 
This study was approved by the University of North Carolina at Chapel Hill and Duke 
University institutional review boards and all data processing was completed with strict 
adherence to the Health Insurance Portability and Accountability Act (HIPAA). 
Echocardiogram 
Data from previously obtained two-dimensional (2D), M (motion)-mode Doppler 
transthoracic echocardiograms within the Duke University Health System were used for 
study analysis.  All previously obtained echos were acquired using standardized techniques 
recommended by the American Society of Echocardiography (Nagueh, Middleton, Kopelen, 
Zoghbi, & Quinones, 1997).  All echo image measurements used by the reviewer for the 
following formulas were obtained by echo sonographers nationally certified by the American 
Society of Echocardiography.  The utility and relevance of arterial-ventricular coupling in 
HFpEF were previously reviewed.  The following measurements are incorporated into a 
calculation that estimates ventricular-arterial elastance.   
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Calculation of arterial elastance (Ea), end-systolic pressure volume (ESP) and stroke 
volume (SV) were derived.  The ESP was estimated as 0.90 X systolic blood pressure (SBP) 
by manual cuff at the time of echo as recommended (Chen et al., 2001).  Stroke volume (SV) 
was measured from the LV outflow tract (LVOT) diameter at the pulse wave (PW) Doppler 
signal (Chen et al., 2001).   
Ea = ESP/SV (measure of arterial elastance) 
Ees (ventricular elastance) was calculated using the single-beat method outlined by Chen and 
colleagues (Chen et al., 2001).   
Ees(sb) = (DBP-(Endest*ESP))/(SV*Endest) 
Endest = 0.0275-(0.165*EF)+0.3656*(DBP/ESP)+(0.515*Endavg) 
Endavg = (0.35695*1)+(-7.2266*tn^1)+(74.249*tn^2)+(-
307.39*tn^3)+(684.54*tn^4)+(-856.92*tn^5)+(571.95*tn^6)+(-159.1*tn^7) 
ESP = 0.9 * SBP 
SV (cm³) 
tn (ms) = R wave to flow onset time/R wave to flow end time; determined 
noninvasively from LVOT Doppler waveform 
Statistical Methods 
Baseline characteristics of the case and control cohorts were represented with 
frequency data.  The total number of incident HFpEF identified, those excluded and the most 
common reasons for exclusion are reported.  The total number of controls identified and 
rationale for inclusion and exclusion were reported.  All approximately normally distributed 
variables were displayed as mean and standard deviation, and non-normally distributed 
variables were displayed as median and interquartile range.   
Bivariate associations between case status and biomarkers (SBP DBP, HR, BMI, Ea, 
Ees, Ea/Ees, LAdiam) were assessed using paired t-tests.  Biomarkers with p<0.1 in the 
bivariate analysis were entered into the model in a single multivariable conditional logistic 
regression model for case status.  Using backward elimination, the full model was reduced to 
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the final model, and the final odds ratios are reported.  To assess the validity of pooling the 
two sources of controls (ED and outpatient), we examined whether the effect differed by 
source by adding the interaction between each biomarker and an indicator of source. 
Statistical significance was defined as p<0.05.  Statistical analyses were performed 
using SAS, Inc., 9.4, statistical software (SAS Institute Inc., Cary, North Carolina) and JMP, 
version 11.2.0 (SAS Institute Inc., Cary, North Carolina). 
Results 
Study Population 
Of the 876 potential case patients (incident HFpEF) identified, 624 were excluded 
leaving a case group of 252 incident HFpEF patients eligible for matching.  The most 
common reasons for exclusion included a) evidence of EF<50% on prior echo (n=296, 49%), 
b) no incident HFpEF (n=188, 30%) defined by the HFNEF diagnostic criteria outlined by 
the European Society of Cardiology (Paulus et al., 2007), c) severe mitral or aortic valve 
disease (n=89, 14%).   
Of the potential 1035 control patients that were identified electronically who had 
previously presented to the emergency department, 720 were excluded due to death (67%) or 
echo evidence of EF<50% (20%), leaving 315 eligible for the control group.  Of the potential 
1175 patients identified electronically who had presented to outpatient clinics, 1007 were 
excluded mostly due echo evidence EF<50% (67%), leaving 168 patients eligible for the 
control group.  The rationale for including patients from both emergency department and 
outpatient clinics in the control group was to insure an adequate sample size of potential 
matched patients that previously had an echo completed. 
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The study included 155 matched pairs for a total sample of 310 patients.  The mean 
age for the entire cohort is 69 years (SD 12.56), 74% are female and 60% are Black.  Though 
the groups were matched on age, the control group ended up slightly older than the case 
group (mean of 70 versus 67 years).  In comparing the means of biomarkers at the time of 
echo between the case and control groups, there were statistically significant differences 
between the case-control with regard to SBP, HR, BMI, Ees and LAdiam.  See Table 3.1.   
Table 3.1.  Comparison of biomarkers for the matched case-control 
 
Analysis results 
All effects that had a bivariate p<0.1 were considered and included in the analysis.  
This included DBP, SBP, BMI, LAdiam, Ea, Ees, Ea/Ees.  The final model included Ees and 
LAdiam, selected based on a backward selection retaining effects with p<0.1.   
The results of the conditional logistic regression comparing the case-control suggest 
statistically significant effects of Ees (0.0030) and LAdiam (0.0002).  For Ees, every unit 
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increase is associated with a 30% higher odds, 1.315(CI 1.097, 1.575) of being in the case 
group.  For LAdiam, every unit increase is associated with a 4.57 times of odds (CI 2.0, 
10.22) of being in the case group.  See Table 3.2. 
Table 3.2.  Conditional logistic regression results, combined matched case-control 
 
The interactions between control source and Ees and LAdiam were included to assess 
homogeneity of the effect across sources, and both were found to be non-significant 
(p=0.7557, 0.5108, respectively).   
Discussion 
In comparing characteristics of the matched pairs, the case group had significantly 
higher SBP, HR, BMI, Ees and LAdiam.  These findings are consistent with other studies 
evaluating HFpEF (Borlaug, Olson, et al., 2010; Mohammed et al., 2012; Paulus & Tschope, 
2013).  In the Borlaug, et al., and Mohammed et al., studies, age and gender groups were 
compared in the analysis; however, none of the other studies comparing biomarker of 
incident HFpEF were case-control designs matched on age, race and gender.  Elevated SBP 
has been considered the cause for increased afterload in HFpEF (Hart et al., 2001), however 
ace inhibitors and angiotensin receptor blockers are not effective in reducing mortality but 
microvascular inflammation may have a role (Paulus & Tschope, 2013).  Elevated heart rate 
has been associated with increased cardiovascular death in HFpEF but use of beta blockers 
has not been associated with decreased mortality (Takada et al., 2014).  Ees elevation in 
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HFpEF has been associated with passive myocardial stiffening, fibrosis and increased 
mortality (Borlaug et al., 2009; Mohammed et al., 2014).  Increases in LAdiam in HFpEF 
have been associated with obesity more so than systolic HTN (Stritzke et al., 2009) and 
linked to increases in mortality (Rossi et al., 2006).   
The findings of the conditional logistic regression showed that one unit increases in 
Ees and LAdiam were associated with an increased risk of being in the case group.  Studies 
have demonstrated increases in Ees and LAdiam with older women and suggested that this 
difference was due to age related LV stiffening (Redfield, Jacobsen, Borlaug, Rodeheffer, & 
Kass, 2005).  In this study, even with controlling for age, race and gender, incremental 
increases in Ees and LAdiam were associated with higher odds of being in the case group.  
This suggests changes in Ees and LAdiam are important to monitor regardless of age, race or 
gender. 
Limitations 
A limitation of this study is related to the importance of associated co-morbidities and 
inflammatory markers in studying HFpEF.  Patients with HFpEF often have hypertension, 
diabetes and renal disease.  This study focused primarily on physiologic and 
echocardiographic markers of HFpEF and did not specifically collect data points related to 
co-morbidities or pro-inflammatory markers.  As suggested by Paulus and Tschope, the 
unique characteristics of HFpEF may be caused by inflammation more so than increases in 
LV load.  Future studies that combine markers of inflammation and physiologic performance 
such as LAdiam and Ees, may help define HFpEF.  
Conclusions 
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From this matched case-control study, we found that the case group had significantly 
higher SBP, HR, BMI, Ees and LAdiam and that incremental increases in Ees and LAdiam 
were associated with higher odds of being in the case group, regardless of age, race or 
gender.  The clinical utility of these findings require further investigation with more than one 
data point for comparison and in prospective designs with larger sample sizes. 
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CHAPTER 4 
 
 
PAPER 3: INCIDENT HEART FAILURE PRESERVED EJECTION FRACTION (HFpEF):  
RECOGNIZING KEY PATIENT ATTRIBUTES 
 
 
Overview 
Objectives: 
This study describes patient attributes, physiologic and echocardiographic biomarkers 
associated with incident HFpEF.   
Background: 
The prevalence of HFpEF continues to rise with 50% mortality within 3 years of incident 
hospitalization and the $31billion annual costs of HF are expected to double by 2030.  Yet 
the science continues to build on the understanding of population(s) at greatest risk.   
Methods: 
Incident HFpEF patients (n=252) were retrospectively identified using HFpEF diagnostic 
criteria defined by the European Society of Cardiology, and physiologic biomarkers (systolic 
blood pressure, diastolic blood pressure, heart rate, body mass index) and echocardiogram 
biomarkers (ejection fraction, diastolic function grade, left atrial diameter, arterial-ventricular 
elastance) were collected from previously acquired 2dimentional M-mode Doppler 
echocardiograms and images were re-analyzed for Ea, Ees calculations.  Descriptive statistics 
were used to define characteristics and biomarkers of the incident HFpEF group.  Arterial 
(Ea) and left ventricular (LV) end-systolic (Ees) stiffness, ventricular-arterial coupling 
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(Ea/Ees ratio) were calculated on a group of n=191 patients.  Factors associated with age at 
diagnosis, age at death and time to death were analyzed.   
Results:   
The sample was 58% Black and 73% female, ages 33 to 99 years.  Baseline characteristics 
showed significantly higher age of incident HFpEF in Whites than Blacks (77 vs. 65 years, 
p<0.0001).  This trend was present in both genders, with Black females age 67 years, White 
females age 77 years (p<0.0001) and Black males 62 years, White males 75 years, 
(p=0.0002) .  For biomarkers, with regard to race, heart rate and body mass index was 
significantly higher in Black compared to White patients (p=0.0228, p=0.0012, respectively).  
With regard to gender, measures of Ea, Ees were significantly higher in women compared to 
men (p=0.0004, p=0.0005, respectively).  Of the 252 incident HFpEF patients, 125 (50%) 
died within 2 years of incident HFpEF admission.  The time to death after diagnosis was not 
significantly different between Black and White patients, but the age at death was 
significantly younger for Black patients compared to White patients (72 versus 81 years, 
p=0.0002).   
Conclusions:   
Race significantly impacts the age of incident HFpEF diagnosis and time at death.   Future 
incident HFpEF studies, when possible, need to include diverse study samples with careful 
attention to diagnostic criteria and screening techniques. 
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PAPER 3: INCIDENT HEART FAILURE PRESERVED EJECTION FRACTION (HFpEF):  
RECOGNIZING KEY PATIENT ATTRIBUTES 
 
 
Objective 
This manuscript presents an analysis of incident HFpEF patients previously 
discharged with heart failure preserved ejection fraction (HFpEF), defined by diagnostic 
guidelines from the European Society of Cardiology (ESC) and inclusive of a diverse study 
sample, reporting on baseline characteristics, echo biomarkers, markers of ventricular-arterial 
coupling and details of death. 
Background 
HFpEF is a progressive disorder responsible for at least 50% of all hospital 
admissions for heart failure (HF) and will likely become the predominant HF in coming years 
(Oktay & Shah, 2014; Owan et al., 2006).  Although the increase in prevalence of HFpEF is 
frequently attributed to the aging population, diverse populations are frequently understudied 
and controversy exists on the populations most affected (Kitzman & Upadhya, 2014).  In 
addition, there are multiple co-morbidities that impact those most at risk (Paulus & Tschope, 
2013).  Studies that incorporate specific measures, such as biomarkers associated with 
HFpEF into age, race and sex stratified samples will likely provide normative data that can 
be expanded upon to help explain this heterogeneous syndrome (Borlaug et al., 2009; Chang 
et al., 2014). 
Concise description and measurement of biomarkers that defines incident heart failure 
preserved ejection fraction (HFpEF), (ejection fraction >50%), in a representative sample of 
the population is essential to identifying early markers of impending HFpEF.  First, the most 
commonly used diagnostic criteria for HFpEF is the Framingham Criteria published in 1971 
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(McKee et al., 1971)  This criteria is not specific to HFpEF and does not use specific 
echocardiographic parameters.  Second, in the current literature, inconsistencies exist, in the 
population(s) most affected by HFpEF (East et al., 2004; Gurwitz et al., 2013), yet studies 
that set the priority of including a broad range of age and race samples into the design are 
few.  This study focuses on the combination of physiologic and echocardiographic indicators 
associated with HFpEF within a diverse study group. 
Pro-inflammatory markers such as interleukin 6 and tumor necrosis factor α have 
been found to be associated with incident HFpEF (Kalogeropoulos et al., 2010) and 
comorbidities such as diabetes, hypertension and kidney disease are frequently associated 
with this syndrome (Paulus & Tschope, 2013).  Thus, multiple systems are involved in 
explaining the etiology and heterogeneity of incident HFpEF (Gladden et al., 2014).  To 
study one aspect of this complex syndrome, identifying feasible markers of cardiac 
physiology associated with HFpEF within a representative sample is indicated.  In 
conjunction, diagnostic criteria that incorporate these markers will provide clarity to defining 
unique characteristics of incident HFpEF patients.   
Ejection fraction (EF), measured from ventricular volume and dependent upon load 
(Braunwald, 2001), is a commonly used parameter to define left ventricular (LV) 
contractility and classify mortality risk, prognosis and treatment (Yancy et al., 2013).  
However, EF may not account for varying degrees of systolic or diastolic function that 
impact contractility such as ventricular size, physiologic parameters, myocardial contractility 
and afterload (Borlaug & Paulus, 2011; Ky et al., 2013).  Invasive hemodynamic 
measurement is the gold standard to reflect LV performance, but noninvasive methods have 
also been validated (Chen et al., 2001; Ky et al., 2013; Nagueh et al., 2009). 
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In addition to diastolic dysfunction (DD), measures of LV end diastolic volume that 
incorporate LV size, end-systolic pressure and volume are key attributes to consider in 
measuring LV contractility (Borlaug & Kass, 2008).  Ejection fraction (EF) is the most 
commonly used to define LV function as a volumetric measure, but does not incorporate LV 
size, pressure and volume throughout systole (contraction) and diastole (relaxation) (Borlaug, 
2014; Ky et al., 2013).  Used in conjunction with EF, measures that incorporate LV volume, 
load and contractility into a measure of ventricular elastance (stiffness) is reflected in Ees 
(Gladden et al., 2014).  In addition to Ees, linking end-systolic pressure-volume to end 
diastolic volume incorporates afterload and is reflected in measuring arterial elastance (Ea).  
Ea and Ees provide a method to explain and measure the interaction arterial-ventricular 
coupling.  Cardiac performance is greatly influenced by the ventricular-arterial coupling, 
measured by the Ea/Ees ratio (Borlaug & Kass, 2011; Ky et al., 2013).  The Ees, Ea and 
ventricular-arterial coupling have been studied in patients with HTN (Borlaug et al., 2009), 
older White patients (Borlaug & Redfield, 2011) and HFrEF (Ky et al., 2013) but not yet in a 
racially diverse, age stratified populations over time. 
Use of consistent and clearly defined diagnostic criteria in addition to reproducible 
measures of LV function are required to build on the current understanding of HFpEF 
(Gladden et al., 2014).  Diagnostic criteria outlined by the European Society of Cardiology 
(ESC) incorporate clinical symptoms and specific noninvasive echo markers (Paulus et al., 
2007).  The criteria specifically outlines the importance of early mitral valve annular velocity 
(E’), and the ratio of E (early LV filling)/E’ in estimating LV filling pressures (Nagueh et al., 
2009).  Evidence of E/e’>15 is diagnostic of LV DD and E/e’<8 is diagnostic of absence of 
HFpEF and E/e’ ranges from 8-15 are suggestive of LV DD that require further evaluation 
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with biomarkers such as E/A ratio or brain natriuretic peptide (BNP) (Paulus et al., 2007).  
Given that there are limited studies that incorporate diverse samples in HFpEF trials and that 
there is inconsistent use diagnostic criteria to define the study population, this study was 
designed to use ESC guidelines to identify patients with incident HFpEF and stratify them by 
age, race and sex and to describe patient characteristics, physiologic and echocardiographic 
biomarkers associated with incident HFpEF diagnosis and time to death after incident HFpEF 
diagnosis.  
Methods 
Study population 
Patients discharged with incident (first episode of) HFpEF, identified by International 
Classification of Diseases, 9
th
 revision, Clinical Modification (ICD-9_CM) code book with 
codes for 428.30 (diastolic heart failure, unspecified), 428.31 (acute diastolic heart failure), 
428.32 (chronic diastolic heart failure), 428.33 (acute on chronic diastolic heart failure) from 
an academic university in the southest, from January 1, 2007-January 1, 2014 were 
identified.  This time range was selected to insure an adequate study sample and because 
protocols were improved before this time period.  To be enrolled, the medical record of each 
patient discharged with incident HFpEF was verified by the reviewer incorporating the 
European Society of Cardiology diagnostic criteria for heart failure normal ejection fraction 
(Paulus et al., 2007) and met ICD-9 criteria.   
Because this retrospective evaluation specifically focused on biomarkers leading to 
incident (first episode) HFpEF patients were excluded if chart review indicated prior HF 
hospitalization for either HFpEF or heart failure reduced ejection fraction (HFrEF), prior 
echo ejection fraction (EF)<50%, if diastolic function, pulse wave or LV outflow tract 
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imaging could not be obtained from the echocardiogram, presence of severe moderate/severe 
mitral valve disease, history of aortic or mitral valve surgery or vegetation, heart 
transplantation, hypertrophic obstructive cardiomyopathy, persistent tachycardia due to 
chronic atrial fibrillation, congenital heart disease, severe pulmonary arterial hypertension 
(not due to diastolic dysfunction), connective tissue disorders such as rheumatoid arthritis, 
advanced malignancy, shock. 
All study data were extracted from pre-existing electronic sources that included a 
storage data base, medical record, echocardiogram database and imaging database.  Within 
the medical record, race was typically self reported when a patient account was created 
within the health system.  An a priori objective of a racially representative study group 
relative to the geographic location was operationalized into the study design.  That is, close 
attention was focused on the consistency of the study sample and the demographic outlined 
by the 2012 U.S. Census Data, in Durham County, that describes the general population as 
38% White, 41% Black and 14% Hispanic (Commerce, 2012).  This study was approved by 
the University of North Carolina at Chapel Hill and Duke University institutional review 
boards and all data processing was completed with strict adherence to the Health Insurance 
Portability and Accountability Act (HIPAA). 
Echocardiogram 
Data from previously obtained two-dimensional (2D) M (motion)-mode Doppler 
transthoracic echocardiograms within the health system were used for study analysis.  All 
previously obtained echos were acquired using standardized techniques recommended by the 
American Society of Echocardiography.  All echo image measurements for the following 
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formulas were obtained by two echo sonographers nationally certified by the American 
Society of Echocardiography. 
End-systolic pressure volume (ESP) was estimated as 0.90 X systolic blood pressure (SBP) 
by manual cuff at the time of echo as recommended (Chen et al., 2001).  Stroke volume (SV) 
was measured from the LV outflow tract (LVOT) diameter at the pulse wave (PW) Doppler 
signal (Chen et al., 2001).  Ees was calculated using the single beat method (Chen et al., 
2001). 
Stroke volume (SV)= 
(LVOT diameter²)(0.785)=LVOT area(cm²) 
(LVOT area(cm²)) (TVI)=SV (cm³) 
 
Arterial elastance (Ea) was defined as the ratio of ESP/SV (Lam et al., 2007).   
Ea = ESP/SV 
ESP = 0.9 * SBP 
SV (cm³) 
Ees was calculated using the single-beat method outlined by Chen and colleagues (Chen et 
al., 2001).   
Ees(sb) = (DBP-(Endest*ESP))/(SV*Endest) 
Endest = 0.0275-(0.165*EF)+0.3656*(DBP/ESP)+(0.515*Endavg) 
Endavg = (0.35695*1)+(-7.2266*tn^1)+(74.249*tn^2)+(-
307.39*tn^3)+(684.54*tn^4)+(-856.92*tn^5)+(571.95*tn^6)+(-159.1*tn^7) 
ESP = 0.9 * SBP 
SV (cm³) 
tn (ms) = R wave to flow onset time/R wave to flow end time; determined 
noninvasively from LVOT Doppler waveform 
Ventricular-vascular coupling was defined as Ea/Ees ratio (Antonini-Canterin et al., 
2013; Borlaug & Kass, 2011).  With normal physiologic response the Ea/Ees ratio varies 
from 0.50-1.00 (Borlaug et al., 2009) or 0.60-1.2 to maintain optimal work efficiency 
(Borlaug et al., 2009).  Previous studies have shown that the Ea/Ees ratio decreases in elderly 
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women because ventricular stiffness increases out of proportion to vascular load (Borlaug & 
Kass, 2008). 
Statistical Methods 
Characteristics of the study cohort were described with frequency data and included 
incident HFpEF patients who died for any cause after the incident hospitalization.  T-tests 
were used to compare mean physiologic and echocardiographic biomarkers.  Analysis of 
variance was used to compare mean age of incident HFpEF diagnosis and median age at 
death by race and sex.  Cox regression was used to assess hazard of death by age at 
diagnosis, race and sex.  Statistical significance was defined as p<0.05.  All statistical 
analyses were performed using SAS, Inc., 9.4, statistical software (SAS Institute Inc., Cary, 
North Carolina) and JMP, version 11.2.0 (SAS Institute Inc., Cary, North Carolina). 
Results 
Study Population 
The potential sample for this study included 876 patients whose charts were screened 
and 624 patients were excluded, leaving 252 for the incident HFpEF cohort that met 
inclusion criteria.  The most common reasons for exclusion were:  a) history of echo 
EF<50%, (n=296, 49%), b) incident HFpEF criteria not met, (n=188, 30%), c) severe aortic 
or mitral valve disease (n=89, 14%).  Across the cohort, the mean age was 70 years (14.83) 
and the majority of participants were female (73%) and Black (59%).  Demographic 
characteristics of the study population represented a study group of 252 patients, 59% Black 
and 73% female, ages 33 to 99 years.  See Table 4.1. 
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Table 4.1.  Characteristics of incident HFpEF group 
 
Race, Age at Diagnosis and Time to Death 
The mean age of incident HFpEF for Black patients was 65 years and for White 
patients was 77 years, (p<0.0001).  See Table 4.2.  The mean age of incident HFpEF 
admission for Black females was 67 years, for White females was 77 years, p<0.0001.  The 
mean age of incident HFpEF admission for Black males was 62 years, for White males was 
75 years, p=0.0002.   
Table 4.2.  Age at Diagnosis by Race 
 
Comparing physiologic biomarkers, for Black patients the heart rate and BMI were 
significantly higher compared to White patients (p=0.0228, p=0.0012).  See Table 4.3.  
Comparing echocardiogram biomarkers, for female patients the Ea and Ees, were 
significantly higher compared to males (p=0.0004, 0.0005).  See table 4.4. 
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Table 4.3.  Physiologic biomarkers of the incident HFpEF group 
 
Table 4.4.  Echo biomarkers of the incident HFpEF group 
 
Patients who died for any cause after incident HFpEF admission were studied.  Of 
252 incident HFpEF patients, 125 died (50%) within 2 years.  The median age at death was 
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79 years, (IQR 68, 87).  Of the incident HFpEF patients, 49% of the women died, 50% of the 
men died, 44% of the Blacks died and 57% of the Whites died. 
Using analysis of variance, comparing age at death by sex, the mean age was 77 years 
for females and 76 years for males (p=0.5142).  Comparing age at death by race, the mean 
age was 72 years for Blacks and 81 years for Whites (p=0.0002).  Comparing age at death of 
Black females versus White females, the mean age was 73 years for Black females and 82 
years for White females (p=0.0010).  Comparing age at death of Black males versus White 
males, the mean age was 70 years for Black males and 79 for White males, (p=0.0308).   
Using Cox regression, assessing the hazard of death by race and by sex, the findings were 
non-significant (p=0.3732, p=0.3551, respectively).  However, assessing the hazard of death 
by age at diagnosis, the findings were significant (p<0.0001), that is, for every one unit 
increase in age, there was a 4% higher hazard of death. 
Discussion 
The impact of race in defining the age of diagnosis of incident HFpEF and age at 
death was significant and carried through to age and sex.  In this study, Blacks represented 
58% of the overall study group, had higher BMI and heart rate and were diagnosed with 
incident HFpEF 12 years younger than White patients and age at death was 9 years younger 
for Black patients compared to White patients. 
As compared with other racial groups, Black patients are at increased risk for the 
development of HF (Bibbins-Domingo et al., 2009), at younger ages and with higher 
prevalence of DM and HTN (Thomas et al., 2011).  Most HFpEF studies have limited 
representation of Black patients and subsequently limited understanding of the factors that 
contribute to HFpEF (Shah, 2012).  In the Atherosclerosis Risk in Communities Study 
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(ARIC), evaluating decompensated HF due to HFrEF and HFpEF from 4 regional 
communities in the United States (Forsyth County, North Carolina, Jackson, Mississippi, 
Minneapolis, Minnesota and Washington County, Maryland) showed that white women had 
the highest proportion of HFpEF admissions (70%) (Chang et al., 2014).  In the analysis 
section of this study, it states that because Minneapolis and Washington County were 
predominately white, Blacks from the 2 counties were not included in the final analysis 
(Chang et al., 2014).  However when reporting the proportion of HFpEF admissions as 
predominately 70% White women, it is unclear how the Blacks in Forsyth County, North 
Carolina (20% Black) and Jackson, Mississippi (61% Black) were weighted in the analysis.  
That is, it is unclear if the proportion of Black and White patients in each location were 
compared or if the HFpEF proportion was calculated from the total number of Black and 
White patients enrolled in the study.  In a subgroup analysis of ARIC, only Black patients 
were included (Gupta et al., 2013).  But of the 6168 records reviewed in the ARIC trial, and a 
cohort sample in Jackson, Mississippi of 2445 patients, only 85 HFpEF patients and 31 
HFrEF patients were included in the subgroup analysis (Gupta et al., 2013). 
Racial and ethnic differences in HF mortality have been inconsistent with some 
studies reporting similar or lower survival for Black patients compared to White patients and 
some studies suggesting no difference in survival (East et al., 2004; Yancy et al., 2008).  In 
the East et al., study, the mortality rate for Black HFpEF patients was 34% higher compared 
to White patients (East et al., 2004).  In the Yancy et al., study, the post discharge outcomes 
between Black and White patients were similar (Yancy et al., 2008).  
Based on a retrospective analysis of 78,801 patients from 257 hospitals, Black 
patients developed HF at younger ages, with more cardiovascular risk factors such as HTN, 
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DM and had a greater risk of death, but had similar in-patient mortality and equitable care 
compared to White patients (Thomas et al., 2011).  Therefore, race is a key factor in studying 
incident HFPEF and needs to be incorporated into the design when studying incident HFpEF 
trials/ 
In addition, use of diagnostic criteria, such as the ESC guidelines, in defining incident 
HFpEF and careful attention to the use of ICD-9 codes are critical when identifying incident 
HFpEF study groups.  In this study, of the 876 potential incident HFPEF patients, only 252 
patients were kept in the study group.  Of the patients excluded, 50% had previous echo 
evidence of EF <50% and an additional 30% did not meet diagnostic criteria for incident 
HFpEF, therefore 80% patients identified by ICD-9 code were not incident HFpEF patients 
after chart review.  As large studies use retrospective data based on ICD-9 codes to study 
incident HFpEF, careful attention to patient screening is required to insure that patients with 
incident HFpEF are appropriately included and that HFrEF patients are appropriately 
excluded. 
Limitations 
 This study includes a diverse sample however, did not collect data points specific to 
associated co-morbidities and inflammatory markers.  Given that incident HFpEF is a 
heterogeneous clinical syndrome possibly linked to multiple co-morbid conditions, the 
collection of inflammatory markers would be beneficial in understanding HFpEF etiology. 
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Conclusions 
The results of this study demonstrate the significant impact of race on the age of 
incident HFpEF diagnosis and age at death.  Future studies that prospectively evaluate 
incident HFpEF would benefit from incorporating consistent diagnostic HFpEF criteria, 
selection of a diverse study group, and use of physiologic markers in combination.    
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CHAPTER 5 
 
DISCUSSION AND CONCLUSION 
 
 
Summary 
 
Heart Failure Preserved Ejection Fraction (HFpEF):  An Integrated and Strategic 
Review 
 The first manuscript reviewed key aspects of the literature and state of the science on 
HFpEF.  Areas of review included scope of the problem, pathophysiology, diagnostic 
criteria, biomarkers and the current status of treatment for HFpEF.  The focus of this 
manuscript was developed based on findings from a previously completed pilot study 
evaluating the role of diastolic dysfunction in HFpEF and from a review of the literature that 
found controversy over the populations most affected in addition to under-representation of 
diverse groups in HFpEF trials.  This review noted the changes in pathophysiologic 
understanding between HFrEF and HFpEF, controversies in defining the population(s) most 
affected by HFpEF, and presented a methodology to define and measure the pathophysiology 
of HFpEF.  In addition, the key role of multiple co-morbidities that factor into the 
development of HFpEF was identified.  The calculation of Ees using the single beat 
technique was reported in 2001 (Chen et al., 2001) and describing ventricular-arterial 
stiffening in HFpEF was reported in 2002 (Kawaguchi et al., 2003).  Biomarkers associated 
with HFpEF were reviewed as a description of the single beat method for measuring 
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ventricular elastance and the interaction of arterial-ventricular stiffness.  This manuscript 
highlighted the need for consistent use of diagnostic criteria and presented a very recent 
example of a very large international trial that used a non-specific diagnostic guide in an 
international study to identify HFpEF.   
As a road map to future manuscripts the literature review set the ground work to 
explore HFpEF.  As defined in the dissertation proposal the primary objective of all 
subsequent studies was to identify early markers that precede the development of HFpEF.  
Three primary hypotheses were established, a) the case group would demonstrate differences 
in biomarkers compared to the control group, b) within the subgroups age/race/sex would 
function as moderator that impact the extent to which biomarkers predict HFpEF and c) 
subgroups within the case group would demonstrate significant differences between race in 
age of incident HFpEF diagnosis.  The first two hypotheses were addressed in manuscript 2 
and the third hypothesis was addressed in manuscript 3.  As outlined in the literature review, 
future studies that include diverse populations, use HFpEF diagnostic guidelines, incorporate 
consider pro-inflammatory markers and use biomarkers that reflect arterial-ventricular 
coupling will likely have a significant impact on HFpEF. 
Comparing Novel Biomarkers Associated with Heart Failure Preserved Ejection 
Fraction (HFpEF):  A Matched Case-Control Study 
 The second manuscript presented the results of an observational retrospective 
matched case-control analysis comparing patients with an incident HFpEF to a control group 
with no prior history of HFrEF or HFpEF.  The groups were matched 1:1 by age (within 3 
years), race, sex and timing of echo and the results suggested statistically significant 
differences in biomarkers between the case and control groups.  This study demonstrated that 
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measures of ventricular-arterial coupling could feasibly be obtained from routinely acquired 
echo and that Ees and LAdiam may be important markers to evaluate over time, however the 
clinical utility of Ees and LAdiam require further study with prospective designs. 
Incident Heart Failure Preserved Ejection Fraction (HFpEF):  Recognizing Key Patient 
Attributes 
This manuscript focused on patient attributes of age, race and sex and measures of 
physiologic and echocardiographic biomarkers in defining the patient population of incident 
HFpEF.   The analysis demonstrated the key role of race in describing the age if incident 
HFpEF diagnosis and age at death.  This study also demonstrated the importance of 
confirming incident HFpEF when patients are selected retrospectively by ICD-9 codes.  
Although this study did not incorporate co-morbidities in defining the incident HFpEF group, 
future studies that incorporate pro-inflammatory markers that result from co-morbid 
conditions in addition to markers of physiology such as Ea and Ees, within diverse samples, 
will add to understanding the complex syndrome of incident HFpEF.  .  
Implications for Nursing Research 
There are two distinct areas that appear to have great potential for nurses in furthering the 
study of ventricular-arterial coupling.  The effect of co-morbidities and the impact of 
neurohormonal activation have not been extensively studied in the setting of arterial 
ventricular elastance.  Nor has the effect of acute and chronic stress on Ea, Ees and Ea/Ees.  
Considering markers such as waist circumference and cortisol as covariates to Ea, Ees in 
studying the impact of stress on incident HFpEF has not been explored widely.  There is 
substantial evidence in the literature that describes pro-inflammatory markers and stress in 
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the context of the context of co-morbid conditions, however, a marker of physiology such as 
ventricular-arterial coupling has not been evaluated.    
A second area of future nursing research may be studying echo, co-morbid conditions 
and genetic markers in addition to physiologic measurements associated with incident 
HFpEF patients.  By using genetic information, physiologic biomarkers within the context of 
know co-morbid conditions, new insights into the phenotype of HFpEF are likely to emerge.  
Cath Gen is a pre-existing data warehouse that stores both genetic samples linked to 
biomarkers from cardiac catheterization.   
Implications for Nursing Practice 
The utility of using arterial-ventricular coupling in the clinical management of 
HFpEF patients may be an important aspect of clinical care for nurses and nurse 
practitioners.  For patients who are asymptomatic or difficult to assess functionally, the use 
of Ea Ees biomarkers in defining physiologic state in conjunction with monitoring symptoms 
may serve a very important role in patient clinical management.   
The nurse’s role as educator may be especially important in this setting.  Helping 
patients understand the complexity of HFpEF that requires consistent use of medications, 
regular monitoring of home BP and dietary modification will significantly impact care.   
Nurses could also be instrumental in helping patients find avenues for adequate 
support.  HF is a progressive illness that can be debilitating without adequate monitoring and 
care.  Effective management requires a great deal of patient education and ongoing 
monitoring. 
In addition, although not discussed within the context of this dissertation, nursing 
interventions to reduce stress may have an indication in this patient population.  Interventions 
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such as relaxation, exercise and yoga have all been associated with decreasing inflammatory 
markers and improvements in blood pressure control (Kiecolt-Glaser et al., 2010; Okonta, 
2012; Tyagi & Cohen, 2014).  Interventions involving nurses need further investigation. 
Conclusion 
 HFpEF is a major public health issue with serious mortality and fiscal implications 
(Dunlay & Roger, 2014).  Patients with HFpEF likely have multiple phenotypes within 
multiple co-morbidities that explain this heterogeneous syndrome (Gladden et al., 2014; 
Paulus & Tschope, 2013).  Concise use of diagnostic guidelines in studies that employ 
diverse research designs, with biomarkers associated with HFpEF will contribute to our 
current understanding of the types of patients most affected and help identify those at risk. 
Findings from the literature review suggested that gaps exist in HFpEF research in the 
identification of biomarkers that predict risk, consistent use of diagnostic guidelines, and 
study designs that incorporate race.  Given that HFpEF is a heterogeneous syndrome, clearly 
defined guidelines and stratified samples are essential.  Regional variation in HFpEF patient 
characteristics is expected.  However, when possible, ensuring an adequately sampled 
population would help provide insight into HFpEF patient characteristics.   
 In the second manuscript that reported the findings of the matched case-control 
analysis using conditional logistic regression suggests that specific biomarkers; suggested 
that patients in the case group had higher SBP, HR, BMI, Ees and LAdiam and that 
incremental increases in Ees and LAdiam were associated with a higher odds of being in the 
case group.   
 In the third manuscript that reported on key patient attributes of incident HFpEF, 
statistically significant differences in age of diagnosis of incident HFpEF and age at death 
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were demonstrated when comparing Black and White patients.  There were also significant 
differences that carried through to gender in that Black women and men were diagnosed with 
incident HFpEF significantly younger than White women and men.   
 To conclude, the incidence of HFpEF continues to increase, yet no specific treatment 
modality other than symptom management has been effective.  Multiple co-morbidities factor 
into the context of etiology and pro-inflammatory markers likely have a role.  Race is a key 
patient attribute in understanding the phenotype of incident HFpEF. 
The matched-case control study suggested statistical significance with Ees and 
LAdiam and analysis of the incident HFpEF group demonstrated the statistically significant 
role of race in age of diagnosis and age at death.  Although markers such as Ea and LAdiam 
do not comprehensively reflect the physiologic impact of the multiple systems involved with 
incident HFpEF, they may reflect one aspect of this complex clinical phenomenon that can 
be measured over time.  Future studies that prospectively test Ea, Ees, LAdiam, in the 
context of racially diverse samples, considering co-morbidities and use consistent diagnostic 
criteria, will significantly impact the trajectory of HFpEF. 
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Appendix A 
 
Appendix A. – List of Abbreviations (alphabetically) 
Term Abbreviation 
American College of Cardiology ACC 
American College of Cardiology Foundation ACCF 
American Heart Association AHA 
American Society of Echocardiography ASE 
Angiotensin Receptor Blockers ARB 
Arterial Elastance Ea(mmHg/ml) 
Arterial/Ventricular Elastance Ea/Ees(ratio) 
Atrial Fibrillation AF 
Body Mass Index BMI(kg/m²) 
Brain Natriuretic Peptide BNP(pg/mL) 
Cardiac Magnetic Resonance Imaging cMRI 
Cardiac Output CO(L/min) 
Coronary Artery Disease CAD 
Creatinine Clearance CrCl(ml/min) 
Diabetes DM 
Diastolic Dysfunction DD(grade) 
Diastolic Blood Pressure DBP(mmHg) 
Early (E) and late (A) diastolic filling  E/A ratio 
Early Mitral Valve Annular Velocity (e’)(cm/s) 
Early Ventricular Filling  E(cm/s) 
Ejection Fraction EF(%) 
End Systolic Pressure Volume ESP 
European Society of Cardiology ESC 
Global Longitudinal Strain GLS(%) 
Health Insurance Portability and Accountability 
Act 
HIPAA 
Heart Failure HF 
Heart Failure Normal Ejection Fraction HFNEF 
Heart Failure Reduced Ejection Fraction HFrEF 
Heart Failure Preserved Ejection Fraction HFpEF 
Heart Rate HR(bpm) 
Hematocrit Hct(%) 
Hemoglobin Hgb(g/dL) 
Hemoglobin A1C HgbA1C(%) 
High Sensitivity C Reactive Protein Hs-CRP (mg/L) 
Homocysteine (µmol/L) 
Hypertension HTN 
Institutional Review Board IRB 
International Classification of Diseases, 9
th
 
revision 
ICD-9 
Isovolumic Relaxation Time IVRT (ms) 
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Late Diastolic Filling A(cm/s) 
Left Atrial Diameter LAdiam(cm) 
Left Atrial Enlargement LAE 
Left Ventricle LV 
Left Atrial LA 
Left Ventricular End Diastolic Pressure LVEDP(mmHg) 
Left Ventricular Filling Pressure E/e’(ratio) 
Left Ventricular Hypertrophy LVH(grade) 
Left Ventricular Outflow Track LVOT(cm) 
Left Ventricular Systolic Elastance Ees(mmHg/ml) 
National Health and Nutrition Examination 
Survery 
NHANES 
Pulmonary Capillary Wedge Pressure PCWP (mmHg) 
Renin-Angiotensin-Aldosterone System RAAS 
Stroke Volume SV(cm³) 
Systolic Blood Pressure SBP(mmHg) 
Treatment of Preserved Cardiac Function in Heart 
Failure with an Aldosterone Antagonist 
TOPCAT 
United States U.S. 
Weight WT(lbs) 
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Appendix B 
 
Appendix B. HFpEF Early Markers Code Sheet 
 
Demographics 
ID# __ __ __ __ 
 1 2 3 4 
Age __ __ 
 5 6 
Race __ 
 7 
Sex __ 
 8 
____________________________________________ 
Date of Admission __ __/__ __ __ __ 
   9 1011 12 13 14 
SBP A __ __ __ 
 15 16 17 
DBP A __ __ __ 
 18 19 20 
HR A __ __ 
 21 22 
BMI A __ __ 
 23 24 
Past Medical History at the time of HFpEF admission 
List of options:  DM 250.00, HTN 401.09, AFIB 427.31 
a. __ __ __: __ __ 
25 26 27 28 29 
b. __ __ __: __ __ 
30 31 32 33 34 
c. __ __ __: __ __ 
35 36 37 38 39 
d. __ __ __: __ __ 
40 41 42 43 44 
_________________________________________________________ 
Echocardiogram 
A. 
Date __ __ /__ __ __ __ 
 45 46 47 48 49 50 
EF 1 __ __ 
 51 52 
LVH 1 __ (0-none, 1-mild, 2-moderate, 3-severe) 
 53 
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DD 1 __ (0-none, 1-grade1, 2-grade2, 3-grade 3/4) 
 54 
SBP 1 __ __ __ 
 55 56 57 
DBP 1 __ __ __ 
 58 59 60 
HR 1 __ __ 
 61 62 
BMI 1 __ __ 
 63 64 
 
 
B. 
Date __ __ /__ __ __ __ 
 65 66 67 68 69 70 
EF 2 __ __ 
 71 72 
LVH 2 __ (0-none, 1-mild, 2-moderate, 3-severe) 
 73 
DD 2 __ (0-none, 1-grade1, 2-grade2, 3-grade 3/4) 
 74 
SBP 2 __ __ __ 
 75 76 77 
DBP 2 __ __ __ 
 78 77 79 
HR 2 __ __ 
 80 81 
BMI 2 __ __ 
 82 83 
 
C.  
Date __ __ /__ __ __ __ 
 84 85 86 87 88 89 
EF 3 __ __ 
 90 91 
LVH 3 __ (0-none, 1-mild, 2-moderate, 3-severe) 
 92 
DD 3 __ (0-none, 1-grade1, 2-grade2, 3-grade 3/4) 
 93 
SBP 3 __ __ __ 
 94 95 96  
 72 
DBP 3 __ __ __ 
 97 98 99 
HR 3 __ __ 
 100 101 
BMI 3 __ __ 
 102 103 
 
D. 
Date __ __ /__ __ __ __ 
 104 105 106 107 108 109 
EF 4 __ __ 
 110 111 
LVH 4 __ (0-none, 1-mild, 2-moderate, 3-severe) 
 112 
DD 4 __ (0-none, 1-grade1, 2-grade2, 3-grade 3/4) 
 113 
SBP 4 __ __ __ 
 114 115 116 
DBP 4 __ __ __ 
 117 118 119 
HR 4 __ __ 
 119 120 
BMI 4 __ __ 
 121 122 
________________________________________________________ 
 
Echocardiogram database 
Echocardiogram #1 
Date  __ __ /__ __ __ __ 
 123 124 125 126 127 128 
Early ventricular filling (E)  __ __ __ 
    129 130 131 
Late diastolic filling (A)  __ __ __ 
    132 133 134 
Early mitral valve annular velocity (E’)  __ __ __ 
      135 136 17 
LV filling pressure (E/E’)  __ __ __ 
    138 139 140 
Arterial elastance (Ea)  __ __ __ 
    141 142 143 
LV systolic elastance (Ees)  __ __ __ 
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    144 145 146 
Arterial/ventricular elastance (Ea/Ees)  __ __ __ 
      147 148 149 
Mean LV end diastolic pressure (mLVEDP)  __ __ __ 
      150 151 152 
Mean pulmonary capillary wedge pressure (mPCWP)  __ __ __ 
        153 154 155 
LV ejection fraction (LVEF)  __ __ __ 
    156 157 158 
Global longitudinal strain (strain %) __ __ __ 
     159 160 161 
LV hypertrophy (LVH)  __ __ __ 
    162 163 164 
 
Echocardiogram #2 
Date  __ __ /__ __ __ __ 
 165 166 167 168 169 170 
Early ventricular filling (E)  __ __ __ 
    171 172 173 
Late diastolic filling (A)  __ __ __ 
    174 175 176 
Early mitral valve annular velocity (E’)  __ __ __ 
      177 178 179 
LV filling pressure (E/E’)  __ __ __ 
    180 181 182 
Arterial elastance (Ea)  __ __ __ 
    183 184 185 
LV systolic elastance (Ees)  __ __ __ 
    186 187 188 
Arterial/ventricular elastance (Ea/Ees)  __ __ __ 
      189 190 191 
Mean LV end diastolic pressure (mLVEDP)  __ __ __ 
      192 193 194 
Mean pulmonary capillary wedge pressure (mPCWP)  __ __ __ 
        195 196 197 
LV ejection fraction (LVEF)  __ __ __ 
    198 199 200 
Global longitudinal strain (strain %) __ __ __ 
     201 202 203 
LV hypertrophy (LVH)  __ __ __ 
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    204 205 206 
 
Echocardiogram #3 
Date  __ __ /__ __ __ __ 
 207 208 209 210 211 212 
Early ventricular filling (E)  __ __ __ 
    213 214 215 
Late diastolic filling (A)  __ __ __ 
    216 217 218 
Early mitral valve annular velocity (E’)  __ __ __ 
      219 220 221 
LV filling pressure (E/E’)  __ __ __ 
    222 223 224 
Arterial elastance (Ea)  __ __ __ 
    225 226 227 
LV systolic elastance (Ees)  __ __ __ 
    228 229 230 
Arterial/ventricular elastance (Ea/Ees)  __ __ __ 
      231 232 233 
Mean LV end diastolic pressure (mLVEDP)  __ __ __ 
      234 235 236 
Mean pulmonary capillary wedge pressure (mPCWP)  __ __ __ 
237 238 239 
LV ejection fraction (LVEF)  __ __ __ 
    240 241 242 
Global longitudinal strain (strain %) __ __ __ 
     243 244 245 
LV hypertrophy (LVH)  __ __ __ 
    246 247 248 
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